1

THE TIME COURSE OF THERAPEUTIC INTERVENTIONS FOR COVID-19

Binh T. Ngo, M.D.1,2,* Binh.ngo@med.usc.edu

Paul Marik, M.D., F.C.C.P., F.C.C.M. Eastern Virginia Medical School| Department of Internal Medicine| Chief, Pulmonary and Critical Care Medicine| 825 Fairfax Ave, Rm 575, Norfolk, VA 23507| marikpe@evms.edu

Pierre Kory, M.D., M.P.A Pulmonary and Critical Care Medicine Aurora St. Luke's Medical Center Milwaukee, Wisconsin . pierrekory@icloud.com

Leland Shapiro, M.D.

Rocky Mountain Regional Veterans Affairs Medical Center in Aurora, CO and University of Colorado Anschutz Medical Campus in Aurora, CO Supported by The Emily Foundation in Boston, MA lelandshapiro@cuanschutz.edu

> Denise Brennan-Rieder P.h.D. CoronaTracker Community Research Group dbrennanrieder@gmail.com

> > Raphael Thomadsen, P.h.D. Washington University in St. Louis thomadsen@wustl.edu

2

Jose Iglesias, D.O., F.A.S.N. Jersey Shore University Medical Center, Neptune NJ, Hackensack Meridian School of Medicine at Seton Hall Jiglesias23@gmail.com

> Stephen Ditmore, B.A. Parkchester Times stephen.ditmore@gmail.com

Marc Rendell, M.D.2,* The Rose Salter Medical Research Foundation Newport Coast, CA 92657 rendell@asndi.com

Joseph Varon, M.D., FACP, FCCP, FCCM, FRSM United Memorial Medical Center University of Texas School of Medicine Houston, Texas, USA joevaron@roamer.net

> Michael Dubé, M.D.1 mdube@med.usc.edu

Neha Nanda, M.D.1 Neha.nanda@med.usc.edu

Gino In, M.D., M.P.H.1 Gino.In@med.usc.edu

Daniel Arkfeld,M.D. 1 arkfeld@med.usc.edu

Preet Chaudhary, M.D.1

Preet.chaudhary@med.usc.edu

Vito M. Campese, M.D. 1 campese@med.usc.edu

Diana L. Hanna, M.D. 1 Diana.Hanna@med.usc.edu

David E. Sawcer, M.D. Ph.D.1 David.sawcer@med.usc.edu

Glenn Ehresmann, M.D.1 Glenn.ehresmann@med.usc.edu

David Peng, M.D., M.P.H.1 David.Peng@med.usc.edu

Miroslaw Smogorewski, M.D.1 smogorze@med.usc.edu

April Armstrong, M.D., M.P.H.1 April.armstrong@med.usc.edu

Rajkumar Dasgupta, M.D.1 "Dasgupta, Rajkumar" <rdasgupt@med.usc.edu>

> Fred Sattler, M.D.1 fsattler@usc.edu

Cristina Mussini, M.D. University of Modena and Reggio Emilia in Italy Cristina.mussini@unimore.it

Oriol Mitja, Ph.D. Hospital Universitari Germans Trias i Pujol Badalona, Spain

omitja@flsida.org

Vicente Soriano, M.D. Ph.D. UNIR Health Sciences School & Medical Center C/ Almansa 101 Madrid 28040, Spain Vicente.soriano@unir.net

> Nicolas Peschanski, M.D., Ph.D UniversityHospital of Rennes Rennes, France nicolas.peschanski@chu-rennes.fr

Gilles Hayem, M.D. Hôpital Paris Saint-. Joseph, 75014 Paris, France. ghayem@ghpsj.fr

Marco Confalonieri, M.D. Azienda Ospedaliero-Universitaria di Trieste Trieste, Italia marco.confalonieri@asugi.sanita.fvg.it

Maria Carmela Piccirillo, M.D. Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale Napoli, Italia m.piccirillo@istitutotumori.na.it

Antonio Lobo-Ferreira, M.D., Ph.D. Unidade de Investigação Cardiovascular (UniC), Faculdade de Medicina da Universidade do Porto, Centro Hospitalar Universitário de São João, Porto, and Hospital Rainha Santa Isabel, Marco de Canaveses, Portugal Aloboferreira@gmail.com

> Iraldo Bello Rivero M.Sc., Ph.D. Department of Clinical Investigations Center for Genetic Engineering and Biotechnology,

> Ave 31 e/ 158 and 190. Cubanacan, Playa, 10600 Havana, Cuba. iraldo.bello@cigb.edu.cu

> > Eivind H. Vinjevoll, M.D. Volda Hospital HMR, Norway. Eivind.vinjevoll@gmail.com

Daniel Griffin, M.D., Ph.D.^{*,3} ProHEALTH, an OPTUM Company Columbia University College of Physicians and Surgeons Email: danielgriffinmd@gmail.com

Ivan FN Hung, MBChB, M.D., MRCP, FRCP.^{*,3} Li Ka Shing Faculty of Medicine University of Hong Kong Ivanhung@hku.hk

From the Keck Medical School of USC
 From the Rose Salter Medical Research Foundation

 CoSenior author

* Corresponding author

6

ABSTRACT

BACKGROUND. The spread of COVID-19 from Wuhan China, has been alarmingly rapid. Epidemiologic techniques succeeded in containing the disease in China, but efforts have not been as successful in the rest of the World. As of November 1, 2020, there have been 45,942,902 confirmed cases of COVID-19, resulting in 1,192,644 deaths worldwide. Projections are for continued new infections and deaths if no effective therapeutic interventions can be initiated over the next several months. We performed a systematic review to determine the potential time course for development of treatments and vaccines, focusing on availability now and by year end 2020.

METHODS Clinical Trials: We reviewed up-to-date information from several sources to identify potential treatments for COVID-19: The Reagan-Udall Expanded Access Navigator COVID-19 Treatment Hub was used to track the efforts of companies to develop agents. We focused on trials completed as of September 15, 2020 on identified agents We used several different sources: (A) covid-trials.org, then validated results on (B) clinicaltrials.gov and the (C) World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP). We excluded studies which were clearly observational, with no randomization, control, or comparison group. We further set a cutoff of 100 for numbers of subjects, since smaller trial size could lack statistical power to establish superiority of the intervention over the control.

Publications: We searched for all published trial results on pubmed.gov and on medRxiv, the preprint server, and used a targeted GoogleTM search to find announcements of unpublished trial results

RESULTS

Clinical Trials in Recruitment: We identified 663 trials currently in recruitment phase with subject size of 100 or more. Of these, 108 were directed at prevention in healthy individuals, 82 were classified as treatment of outpatients with documented infection, and 330 were for treatment of hospitalized inpatients.

Clinical trials Completed: As of November 15, 2020, there were only 80 studies with 100 or more subjects, including ; 49 trials in hospitalized patients, 9 directed at outpatients, and 10 prevention studies,

Published Data: As of November 1, 2020 we found 82 publications reporting findings in human studies on 12 classes of agents, and on 7 vaccines (See TABLE 2). There were 44 randomized or active controlled studies. The rest were retrospective observational analyses. Only 14 publications dealt with outpatient care, including 7 vaccine reports; the rest were all in hospitalized patients.

Available Treatments. At this time, remdesivir and convalescent plasma have been granted emergency use authorization in the U.S.A., solely for hospitalized patients. There is also support for glucocorticoid treatment of the COVID-19 respiratory distress syndrome. No treatments or prophylaxis are offered for outpatients.

CONCLUSION. COVID-19 is propagated primarily by infected ambulatory individuals. There have been no options brought forward for prevention and non-hospital treatment with only a few randomized, controlled outpatient studies expected to yield results in time to impact on the continuing pandemic by the end of 2020. It will be necessary for public health authorities to make hard decisions, with limited data, to prevent the continued spread of the disease. The choices will be hardest when dealing

8

with possible early release of safe and effective vaccines which would, of course, be of greatest benefit to the World's population.

Keywords: Coronavirus, COVID-19, SARS-Cov-2, remdesivir, hydroxychloroquine, favipiravir

INTRODUCTION

SARS-Cov-2 spread with extraordinary speed from its origin in December 2019 in Wuhan, China. As of November 1, 2020, there have been 45,942,902 confirmed cases of COVID-19, resulting in 1,192,644 deaths worldwide affecting 220 countries and territories (1). This viral and multisystemic illness produces mild or no symptoms in about 80% of infected individuals, but, in about 20% manifests as pneumonia, which may progress to acute respiratory failure requiring assisted mechanical ventilation in up to 5% of patients (2). Symptomatic COVID-19 exhibits a characteristic sequence of events related to the primary viral attack, manifesting as an influenza-like illness with cough, fever, myalgias and fatigue. In patients destined for severe disease, within seven to 10 days of onset of symptoms, bilateral multiple lobar and subsegmental areas of consolidation are typically seen on chest computed tomography (CT) (See Figure 1) (3). Pneumonia can rapidly progress to acute respiratory failure with elevated cytokines suggesting an immune reaction as probable cause (4). Additionally, a coagulopathy develops which can affect the lungs and other organs, including triggering cerebrovascular thrombosis (5).

9

In mainland China, vigorous efforts to contain the spread of COVID-19 by home isolation, closure of business activity, travel bans, and tracking and control of contacts succeeded. As of November 1, China has had 91,921 confirmed cases with 4,746 deaths, but the number of new cases declined to low levels since April (1). Similar measures contained the epidemic in Korea, Taiwan and in New Zealand (1). In Hong Kong, one of the most densely populated areas in the world, universal masking, immediate hospitalization and early antiviral treatment for all confirmed cases have minimized the number of confirmed COVID-19 cases to 5,331 in a 7.5 million population with less than 3% requiring ICU care, and 105 fatalities (6). However, the disease was not similarly controlled in the rest of the World, particularly the United States (USA) where, despite only a fifth of the population of China, there have been 8,952,086 confirmed cases of COVID-19 with 228,185 deaths as of November 1, 2020 (1). In the USA, as in China, the response to the pandemic was through reduction of person-to-person contact. Beginning in early March, social gatherings and meetings ended; schools and businesses were closed along with recreation areas, parks, and beaches. These social distancing efforts blunted the spread of the disease, but not with the results achieved in China. Due to economic pressures, epidemiologic containment was relaxed resulting in a significant surge surpassing the original April peak.

Facing the growing crisis in early January, Chinese health authorities began treating patients empirically with agents with demonstrated *in vitro* antiviral activity against coronaviruses and those used during prior outbreaks of SARS 2003, H1N1 influenza of 2009 and MERS 2015(7). The medications included the antimalarial drugs hydroxychloroquine (HCQ) and chloroquine, the human immunodeficiency virus (HIV) protease inhibitor lopanovir-ritanovir (LPV/r), the Russian antiviral umifenovir, and

10

traditional Chinese medical approaches (8). Subsequently, HCQ was widely used to treat COVID-19 throughout the world, despite cautions from numerous regulatory bodies. The scientific basis for their use was *in vitro* evidence of an effect on blocking viral endosomal penetration, as well as a known suppressive benefit on undesirable autoimmune effects (9). Clinical studies thus far have been unsupportive.

Multiple vaccines are in clinical trials to assess safety and effectiveness, but these studies are unlikely to complete Phase III testing and proceed to mass vaccination until early 2021. In view of the continuing daily increase in new cases and deaths, our goal was to assess the options we have at the present time for release of pharmacologic agents to treat and to prevent COVID-19 while awaiting widespread immunization.

METHODS

CLINICAL TRIALS: We reviewed up-to-date information from multiple sources to identify potential treatments for COVID-19: The Reagan-Udall Expanded Access Navigator COVID-19 Treatment Hub was used to track the efforts of companies to develop therapeutic interventions. We searched for investigational trials in active recruitment and those that have completed enrollment. We used (A) covid-

11

trials.org, a registry to collate all trials in real time with data pulled from the International Clinical Trials Registry Platform and all major national registries (10). We cross validated information on (B) clinicaltrials.gov, the registry of clinical trials information maintained by the United States National Library of Medicine. We further cross referenced the trials on (C) the World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP).We excluded studies which were clearly observational for treatment purposes, with no randomization, control or comparison group. We further set a cutoff of 100 for numbers of subjects since smaller trial size typically lacks statistical power to enable regulatory approval. For each trial selected, we documented the setting of patient contact, either hospital or outpatient, the type of control procedure, the date the trial was initially registered, and the proposed date of completion of enrollment.

PUBLISHED TRIAL RESULTS: Our search was carried on the week of November 1, 2020. We identified all publications on pubmed.gov to find peer reviewed articles and on medRxiv to find preprint reports. We further carried out daily Google[™] searches on each potential treatment to find preliminary reports, typically presented as press releases, reviewed by a journalist.

VIRTUAL DISCUSSIONS AMONG CO-AUTHORS: We used the preprint server medRxiv to post a systematic analysis of the development of therapeutic interventions for COVID-19 in order to stimulate diffusion of the manuscript and allow widespread "open source" input from co-authors (11). Successive versions have been posted periodically beginning in late May, 2020 and continuing to date.

12

RESULTS

REVIEW OF CURRENT TRIALS: As of November 1, 2020, we identified 663 trials currently in recruitment phase with subject size of 100 or more (Supplementary Table 1). Of these, 108 were directed at prevention in healthy individuals, 82 were classified as treatment of outpatients with documented infection, and 330 were for treatment of hospitalized inpatients. There were 9 trials focusing on the post discharge Tail phase. The remaining trials were unclear as to intended subjects. There were 44 vaccine trials, 120 trials of HCQ, 31 trials of alternative therapy, 11 trials of colchicine, 31 trials of anticoagulants, 13 trials of the RNA polymerase inhibitor favipiravir (FPV), 18 trials of glucocorticoid, and 53 trials of plasma based products. Closure of enrollment was projected by the end of the year for 105 trials.

COMPLETED TRIALS: As of November 1, 2020, there were 83 trials reporting completion with 100 or more subjects (Supplementary Table 2). Sixteen of these studies were of alternative medications. There were 49 trials in hospitalized patients, 8 directed at outpatients, and 11 prevention studies.

PUBLISHED RESULTS ON COVID-19 TRIALS: As of November 1, 2020 we found 82 publications reporting findings in human studies on 12 classes of agents, and on 7 vaccines (See TABLE 1). There were 44 randomized or active controlled studies. The rest were retrospective observational analyses. Only 14 publications dealt with outpatient care, including 7 vaccine reports; the rest were all in hospitalized patients.

13

In the group of antiviral agents, the largest published randomized, controlled trials were with the intravenously administered RNA polymerase inhibitor remdesivir. The first multicenter trial conducted at ten hospitals in Hubei, China was halted in April due to lack of recruitment after 237 patients enrolled (12). Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 1.23 [95% CI 0.87–1.75], decreased viral load, nor mortality benefit. A double blind, randomized placebo controlled trial of remdesivir, in 1062 moderate to severely ill patients was a carried out by the National Institute of Allergy and Infectious Disease (NIAID) (14). The patients who received remdesivir had a median recovery time of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI, 1.12 to 1.49; P<0.001). P<0.001). The Kaplan-Meier estimates of mortality by 29 days after randomization were 11.4% with remdesivir and 15.2% with placebo (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). On the basis of this trial, the Food and Drug Administration (FDA) issued an emergency authorization for use of remdesivir for COVID-19 hospitalized patients. Subsequently, a report was published showing that in 397 hospitalized patients with moderate to severe disease, there was no difference in outcome comparing patients who received a 5 day course of remdesivir versus a 10 day course (15). There was no placebo arm. The 14 day mortality in the 5 day group was 8% versus 11% in the 10 day group. A different study of remdesivir in hospitalized patients with moderate COVID-19 clinical status showed improved clinical status by day 11 compared to standard of care for a 5 day course of remdesivir, but not for a 10 day course (16). Mortality at 28 days was 1% for patients in the 5 day group, 2% for those in the 10 day group, and 2% for the standard of care group. A retrospective analysis of a cohort of 312 patients with severe disease treated with remdesivir showed a mortality of 7.6%% compared to 12.5% in a different historical retrospective cohort of 818 patients treated with standard of care (17). There has been no data provided on viral clearance for the U.S. remdesivir studies. In early April,

the WHO organized a megatrial, appropriately named Solidarity, to assess four separate treatment options in hospitalized patients: (a) Remdesivir, an intravenously administered inhibitor of RNA polymerase; (b) LPV/R; (c) LPV/R plus Interferon β -1a; and (d) HCQ or Chloroquine (12). Results of the Solidarity Trial were reported by the World Health Organization on October 15, 2020. They found no effect of remdesivir on 28 day mortality, need for mechanical ventilation nor duration of hospitalization in a study including 5451 hospitalized patients (18).

There were two randomized, active control clinical trials in China of the orally administered RNA polymerase inhibitor favipiravir (FVP) (19, 20). In a study of 35 patients receiving FVP, compared to 45 patients receiving LPV/R plus inhaled interferon α , a shorter viral clearance time was found for the FVP arm (median (interquartile range, IQR), 4 (2.5–9) days versus 11 (8–13) days, p < 0.001) (19). The FVP arm also showed significant improvement in chest imaging compared with the control arm, with an improvement rate of 91.4% versus 62.2% (p = 0.004). In a larger Chinese trial comparing 116 patients on FVP to 120 on uniferovir, the 7 day clinical recovery rate was 55.9% for the uniferovir group and 71% in the FVP group (20). The Chinese Health Ministry, after reviewing the studies, concluded that FVP was efficacious against COVID-19. In Japan, a clinical registry containing 1918 hospitalized patients receiving FVP on a compassionate use basis was released on June 2, 2020 (21). There was no control group nor data on viral clearance. Patients were treated on average 3 days post admission to the hospital. The 30 day overall mortality was 11.6%. In Russia, a preliminary study of FVP showed reduced duration of viral shedding, and the drug was approved for clinical treatment beginning in multiple hospitals on June 12, 2020 (22). In India in July, Glenmark[™] announced unpublished data on 150 patients confirming the favorable results of the Chinese studies, and FVP was released for treat-

Japan announced more rapid viral clearance in FVP treated patients.

ment in that country. In late September, a report, still unpublished, of a randomized controlled study in

There were 21 published studies with HCQ. A group in Marseille reported their experience with 3737 patients screened positive for SARS-Cov-2 and immediately treated with HCQ and azithromycin (AZM), after excluding patients at risk of QT prolongation (23). Asymptomatic contacts with positive viral tests were included, so most of their subjects were outpatients seen in their day hospital in addition to those who did require hospitalization. They showed clearance of viral shedding in 89.4% of the patients by ten days. The overall mortality in their population was 0.9%, none in patients under 60 years old, and no sudden cardiac deaths. They had no randomized control population.

There have been many retrospective large observational trials which suggest that hospitalized patients on HCQ have worse outcomes with possible cardiac dysrythmias (See TABLE 1) (27-32). The difficulty in analyzing retrospective observational data is the possibility of selection bias choosing patients who were sicker for treatment.

In a randomized, controlled, Brazilian study, neither HCQ nor HCQ +AZM showed any clinical benefit in mild to moderate COVID-19 hospitalized patients (33). In the randomized RECOVERY trial in 1542 hospitalized patients in the United Kingdom, there was no significant difference in the primary endpoint of 28-day mortality (26.8% HCQ vs. 25% usual care; hazard ratio 1.09 [95% confidence interval 0.96-1.23]; p=0.18) (34). In the Solidarity Trial, there was no benefit of HCQ on mortality (HCQ

16

RR=1.19 (0.89-1.59, p=0.23; 104/947 vs 84/906), need for mechanical ventilation, nor duration of hospitalization(18).

In a retrospective comparison study at NYU Langone Health for all patients admitted between March 2 and April 5, 2020, there was a move to add zinc 100 mg daily to their standard HCQ plus AZM regimen (35). Zinc supplementation has shown benefit in viral diseases both in inhibiting viral replication, improvement of systemic immunity and reduction of duration of common cold symptoms There was a significantly lower mortality (13.1%) among the zinc treated patients compared to those who did not receive zinc (22.8%).

The prevailing current opinion on HCQ treatment of COVID-19 is based almost entirely on in-hospital data, with limited study in outpatients. In one internet-based prevention study, with HCQ given for 5 days to healthy individuals with a significant exposure to SARS-Cov-2, the incidence of new illness compatible with COVID-19 did not differ significantly between participants receiving HCQ (49 of 414 [11.8%]) and those receiving placebo (58 of 407 [14.3%]); absolute difference -2.4 percentage points (95% confidence interval, -7.0 to 2.2; p=0.35) (36). The same group also treated 423 patients with mild symptoms imputed to COVID-19 (37). At 14 days, 24% (49 of 201) of participants receiving HCQ had ongoing symptoms compared with 30% (59 of 194) receiving placebo (p = 0.21).

A study in Spain of 293 patients with PCR-confirmed mild COVID-19, found no difference in viral load nor risk of hospitalization following 6 days HCQ treatment compared to untreated patients (38).

17

The same group treated 1,116 healthy contacts of 672 Covid-19 index cases with HCQ while 1,198 were randomly allocated to usual care (39). There was no significant difference in the primary outcome of PCR-confirmed, symptomatic Covid-19 disease (6.2% usual care vs. 5.7% HCQ; risk ratio 0.89 [95% confidence interval 0.54-1.46]), nor evidence of prevention of SARS-CoV-2 transmission (17.8% usual care vs. 18.7% HCQ).

A large population study in Portugal surveyed all patients on chronic HCQ treatment and cross-verified against a mandatory database of patients registered with COVID-19 (40). The incidence of SARS-CoV-2 infection in patients receiving HCQ was 5.96%, compared to 7.45% in those not so treated. The adjusted odds ratio of a positive PCR test for HCQ chronic treatment was 0.51 (0.37-0.70). A randomized controlled study at the University of Pennsylvania found no evidence of benefit of two months prophylactic treatment with HCQ in 132 hospital workers SARS-Cov-2 infection rate HCQ 6.3% vs placebo 6.6%) (46).

Published results with Lopanovir/ritonavir (LPV/r) in hospitalized patients have been disappointing (47,48). In a randomized trial with 99 patients on LPV/r and 100 receiving standard care, there was no difference in time to clinical improvement, mortality or viral clearance (48). In the RECOVERY trial in 1,596 hospitalized patients there was no significant difference in the primary endpoint of 28-day mortality (22.1% LPV/r vs. 21.3% usual care; relative risk 1.04 [95% confidence interval 0.91-1.18]; (p=0.58) (49). In the Solidarity Study, there was no effect of LPV/r on 28 day mortality LPV/r RR=1.00 (0.79-1.25, p=0.97; 148/1399 vs 146/1372), need for mechanical ventilation nor duration of hospitalization (18).

A possibly more favorable result was obtained in Hong Kong in a study of 86 patients assigned to triple combination therapy with LPV/r plus ribavirin plus interferon β -1 (50). Compared to a control group of 41 patients receiving LPV/r alone, the combination group had a significantly shorter median time from start of study treatment to negative SARS-Cov-2 nasopharyngeal swab (7 days [IQR 5–11]) than the control group (12 days [8–15]; hazard ratio 4.37 [95% CI 1.86–10.24], *p*=0.0010). The time to complete alleviation of symptoms was 4 days [IQR 3–8] in the combination group vs 8 days [7–9] in the control group; HR 3.92 [95% CI 1.66–9.23. This study was interpreted not as supporting LPV/r therapy, but rather focusing on interferon β -1 as the primary treatment modality.

In Cuba, a combination of interferon- α -2b and interferon γ on background therapy of LPV/r and chloroquine was successful in achieving viral clearance in 4 days in 78.6% of the patients compared to 40.6% of those receiving interferon- α -2b alone (53). A study of 81 hospitalized patients in Iran showed 28-day overall mortality significantly lower in an interferon β treated group than the control group (19% vs. 43.6% respectively, *p*= 0.015) (54). Early administration significantly reduced mortal-ity (OR=13.5; 95% CI: 1.5-118). Interferon nasal drops were administered to 2944 medical staff people in Huabei province, with not a single case of COVID-19, but there was no randomized control group (55). Recently, a press release announced that a small British study of nebulized interferon β -1 had succeeded in reducing duration of hospitalization and mortality. In the Solidarity Study of hospitalized patients, there was no effect of interferon on 28 day mortality (IFN RR=1.16 (0.96-1.39, p=0.11; 243/2050 vs 216/2050), need for mechanical ventilation nor duration of hospitalization (18)

19

There have been many observational studies of immunomodulatory therapy with tocilizumab and anakinra to mitigate the pulmonary phase of COVID-19 which have suggested reduction of mortality and need for intubation in hospitalized severe and critically ill patients (31, 57-69). However, in several rtandomized control studies, there has been no benefit with tociliumab (70-72); in the randomized double blind COVACTA trial, there was no benefit of tocilizumab in clinical status, mortality (19.7% tocilizumab vs placebo = 19.4%), nor in ventilator free days (71). In the Cor-Immuno-Toci trial, there was no decrease in mortality at day 28, although there was a suggestion of improvement in the need for mechanical ventilation at day 14 (72). The tocilizumab results in the randomized controlled trials were affected by a higher frequency of glucocorticoid use in the control groups.

Pre-COVID-19, glucocorticoid treatment had been a recognized treatment with mortality benefit for patients in severe respiratory distress (73). In the RECOVERY trial, 2104 patients were randomly allocated to receive dexamethasone for ten days compared to 4321 patients concurrently allocated to usual care (74). Overall, 454 (21.6%) patients randomized to dexamethasone and 1065 (24.6%) patients receiving usual care died within 28 days (age adjusted rate ratio [RR] 0.83; 95% confidence interval [CI] 0.74 to 0.92; p<0.001). Dexamethasone reduced deaths by one-third in the subgroup of patients receiving invasive mechanical ventilation (29.0% vs. 40.7%, RR 0.65 [95% CI 0.51 to 0.82]; p<0.001) and by one-fifth in patients receiving oxygen without invasive mechanical ventilation (21.5% vs. 25.0%, RR 0.80 [95% CI 0.70 to 0.92]; p=0.002), but did not reduce mortality in patients not receiving respiratory support at randomization (17.0% vs.13.2%, RR 1.22 [95% CI 0.93 to 1.61]; p=0.14). Other glucocorticoids have shown similar benefits in COVID-19 patients with acute respiratory failure (75-81), al-

though a short 5 day course of methylprednisolone did not alter the very high mortality in a Brazilian study (79).

Colchicine, an anti-inflammatory agent, suggested benefit in the GRECCO, placebo-controlled, randomized clinical trial of 105 patients (82). The primary clinical end point of deterioration to mechanical ventilation or death was 14% in the control group (7 of 50 patients) and 1.8% in the colchicine group (1 of 55 patients) (odds ratio, 0.11; 95% CI, 0.01-0.96; p = 0.02).

There is also favorable data on convalescent plasma (83-87). A meta-analysis including 4173 patient outcomes across a multinational series of studies concluded that convalescent plasma treatment yielded a 57% reduction in mortality (86). Based on evidence of safety in over 20,000 patients in an expanded access program coordinated by the Mayo Clinic, the U.S. FDA recently issued an emergency authorization for use of convalescent plasma (87). However, convalescent plasma showed no benefit in a randomized controlled trial in India (88). Monoclonal antibodies to the SARS-COV-2 spike protein have been synthesized. Several recent press releases announced initial success in reducing viral loads with these antibodies.

A number of vaccines have reported successful induction of neutralizing antibody and cellular immune responses in early phase trials (91-97). Several vaccines are now in large scale studies preparing for submission for emergency use in the pandemic.

21

DISCUSSION

SARS-Cov-2 overwhelmed medical preparedness for the pandemic. Current projections are for a continuation of new cases and deaths through the end of 2020 (98, 99). Clinical trials to date have focused on hospitalized patients to try to prevent death. The modalities currently having emergency approval for treatment are solely directed at hospitalized patients. It is hoped that the use of remdesivir, convalescent plasma, glucocorticoids, anticoagulation and improved management of COVID-19 respiratory failure will lower the present rate of in hospital mortality which in some series has been as low as 6% but in most hospitals still approaches 20% (78). However, COVID-19 has several phases; the initial viral infection eventually leads to the inflammatory/pulmonary phase which requires hospital treatment. It is essential to change the present dynamic of attempted therapeutic responses to distinguish specific phases (100). In particular, efforts must now focus on prevention and treatment of the initial viral infection so that hospitalization can be avoided. We face a dilemma in having no current prevention nor treatment for outpatients with mild to moderate disease, constituting 80% of the infected population and the primary mode of spread of SARS-Cov-2. The lessons learned in very sick hospitalized patients do not necessarily apply to the earlier viremic phase. Antiviral agents, such as remdesivir and favipiravir, convalescent plasma, and monoclonal antibodies are likely to be most effective during the early stage of viremia, which is prehospitalization.

Vaccines have been the sole hope held out by public health authorities to arrest SARS-Cov-2 in the early viremic phase. Progress on vaccine development has been rapid, but the speed of development

22

does not reduce the challenges of developing a vaccine to be administered to hundreds of millions of people. Certainly the 30 years of as yet unsuccessful efforts to produce an AIDS vaccine illustrate the worst case difficulties. Although neutralizing antibodies and memory T cells can be produced by the vaccine candidate, the demonstration of true protection requires observation and long-term follow-up of an exposed vaccinated population. No matter how rapidly a vaccine advances to Phase III testing, the duration of follow-up cannot be shortened, and for SARS-Cov-2 possibly prolonged due to several factors. First, there is a risk of immune enhancement of infection which occurs when induced antibodies increase entry and internalization of virus into myeloid cells (101). This major complication struck the newly developed dengue vaccine in 2017 (102). Second, the sinister autoimmune pathogenicity of SARS-Cov-2 raises the risk of delayed long-term harm if the virus is not fully and immediately eradicated by the initial immune response to the vaccine. Finally, the duration of protection is an open question. Studies of recurrent coronavirus infections suggest that infection may confer immunity for less than a year (103). For these reasons of needed long term safety observation, the deployment of an effective vaccine could be delayed. Furthermore, efforts to find volunteers for vaccine trials will be hampered if there is no treatment available for placebo treated patients who become infected.

Shortages of testing supplies in the United States have thus far limited the ability to positively diagnose the disease, resulting in the recommendation of home quarantine for the majority of patients with suspicious symptoms. Those shortages are being remedied. Now, there is a need for therapeutic interventions which can be used to treat outpatients with positive COVID-19 tests at the time of initial symptoms, not waiting for deterioration requiring hospital care. The Marseille group treated all outpatients with a positive COVID-19 test early in the viremic phase (23). They provided clinical and

23

virologic data, but without a well-defined control group to justify their treatment with HCQ plus AZM. The NYU group treated all hospitalized patients with HCQ and AZM, and showed an impressive effect of addition of zinc sulfate, but they had no control group for HCQ plus AZM (35). Remdesivir administered intravenously for five days is not a practical daily outpatient treatment; Gilead[©] is attempting to develop an inhaled remdesivir formulation, but those efforts are only now beginning. Favipiravir, a tablet, could be used in early stages of infection and has now been released in Russia and in India, but not in the United States. It has known embryogenic risks, so its use requires restrictions on women of childbearing potential, as is the case with tretinoin for acne and thalidomide for multiple myeloma. Trials with camostat, the serine protease inhibitor, capable of blocking cell entry of SARS-Cov-2, are not due to end till the third or fourth quarter of the year. Similarly, a prevention trial with colchicine is not scheduled to end until the fourth quarter of 2020. Convalescent plasma has been approved for emergency use in hospitalized patients. An infusion could be delivered to outpatients. Monoclonal antiviral neutralizing antibodies based on the same principle are under study to prevent nursing home outbreaks, and have shown initial success in ambulatory patients. But, at this time, no outpatient therapy has been proven safe and effective in a phase III randomized, placebo-controlled study. There are strong arguments to avoid emergency use of agents until trials are completed and analyzed, but the agents suggested are not new. Most are drugs like the interferons, marketed and available for other conditions and with well-known safety profiles. There is a clear need for outpatient therapeutic intervention now.

There is a precedent to resolve the conflict between immediate clinical need and the requirements for rigorous controlled trials to prove efficacy. We should remember that the greatest success in fighting a

pandemic occurred over the past two decades in the battle against the HIV virus which causes AIDS. AIDS was first recognized in 1981 in the MSM (men who have sex with men) community (104). The disease was considered a death sentence. There was widespread fear because there was no treatment, and projections of infection escalated into the millions. The first AIDS remedy was azidothymidine (AZT), synthesized in 1964 in the hope that it would combat cancer. Twenty years later Dr. Samuel Broder, head of the National Cancer Institute, showed that the drug had activity against the HIV virus in vitro (105). Burroughs Wellcome launched a rapidly conceived trial with just 300 patients. They stopped the trial in 16 weeks claiming that more patients survived on AZT. The FDA came under enormous pressure from AIDS activists to make the drug available, and it was approved on March 19, 1987, with only that one trial. It had taken 20 months for the FDA to give approval to release the drug. To this day, the design and results of the trial remain controversial.

The LGBT community continued to battle for early release of other medications to combat the AIDS pandemic. On October 11, 1988, a massive protest occurred at the FDA. It was back then Dr. Anthony Fauci who publicly advanced the idea of a parallel track to make drugs widely available even while studies are progressing: "*Clearly, the standard approach to the design of clinical trials*—*that is, rigid eligibility criteria as well as the strict regulatory aspects that attend clinical trial investigations and drug approval*—*was not well-suited to a novel, largely fatal disease such as this with no effective treatments, and we had many intense discussions about how to make that approach more flexible and ethically sound. One example, which I and others worked closely with the AIDS activists to develop, was called a parallel track for clinical trials. The parallel track concept, which the United States Food and Drug Administration ultimately came to support, meant that there would be the standard type of highly*

25

controlled admission criteria and data collection for the clinical trial of a particular drug. In parallel, however, the drug also could be made available to those who did not meet the trial's strict admission criteria but were still in dire need of any potentially effective intervention, however unproven, for this deadly disease" (106).

The parallel track advocated by Dr. Fauci was adopted. Today, there are 41 drugs or combinations approved by the FDA to treat and to prevent HIV infection. There is still no vaccine. There are now an estimated 1.1 million patients with HIV in the United States, most enjoying near normal life expectancy thanks to the antiviral agents. The CDC has contributed greatly to limit the spread of HIV by advocating safe sex practices, but social distancing is not the norm for HIV. Rather "treatment as prevention" for people with HIV using highly active antiretroviral regimens to prevent transmission as well as pre-exposure prophylaxis with a daily antiviral combination pill are currently endorsed by the CDC and adopted in wide segments of the at risk population 107).

In this pandemic crisis, we appeal to public health authorities to change the dynamic of current studies to outpatient care and to cross institutional, commercial and international boundaries to collate and combine all randomized controlled data submitted for all agents in Europe, China, Russia, Japan, India and other countries, and by competing companies, whether officially published, posted on line, or unpublished to finalize confirmatory results. The Solidarity Trial is a model of what could and should be done to unify a worldwide effort to pursue randomized controlled studies in outpatients. At the same time, agents with favorable preliminary results and no safety issues should be made available through a parallel track. In Russia and India, the parallel track has been fully implemented, with FVP now offered

26

as treatment throughout both countries, even as further confirmatory controlled trials proceed. The interferons are widely available in most countries. If vaccines can be brought forward now, it is reasonable to authorize their use at present in very large parallel track studies in at risk populations, such as healthcare workers and the elderly. China has begun vaccinating their military with one of their vaccines. Russia is proceeding to a voluntary vaccination program. The United Kingdom and the U.S. Centers for Disease Control are considering an emergency authorization program for vaccines before conclusion of the ongoing Phase 3 trials. However, it is unwise to rely solely on the hope for eventual mass vaccination to stop SARS-Cov2. Antiviral medication has succeeded in limiting HIV, and antivirals are just as important as annual vaccination for control of influenza. It is necessary for public health authorities to make hard decisions now despite limited current data and offer outpatient treatments on a broad front with no further delay.

REFERENCES

1) WHO Coronavirus Disease (COVID-19) Dashboard

Data last updated: 2020/11/01 143 PM

2) Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323(13): 1239-1242

3) Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.

4) Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020 Apr 17 https://doi.org/10.1111/jth.14849.

5) Ricardo J, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation storm: Lancet Respir Med 2020; 8(6): e46-e47

6) https://www.nature.com/articles/d41586-020-01248-1

7) Park M, Ryan S, Thwaites RS, et al. COVID-19: Lessons from SARS and MERS Eur J Immun 2020; 50(3): 308-311

8) China National Health Commission. Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition 2020-03-16 12:00:32

9) Liu J, Cao R, Xu M,et al. Cell Discovery. 2020; 6:16 Cell Discovery https://doi.org/10.1038/s41421-020-0156-0www.nature.com/celldisc

10) Thorlund KT, Dron L, Park J et al. A real-time dashboard of clinical trials for COVID-19. Lancet Digital Health 2020; 2: e86-e87 published on line 24 Apr 20 https://doi.org/10.1016/ S2589-7500(20)30086-8

11) Ngo BT, Rendell M. A systematic analysis of the time course to develop treatments for COVID-19medRxiv 2020.05.27.20115238; doi: https://doi.org/10.1101/2020.05.27.20115238

12) Wang Y, Zhang D, Guanhua Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395 (10236): 1569-1578

13) Grein J, Ohmagari N, Shin D et al. Compassionate use of remdesivir for patients with severe Covid-19N Engl J Med 2020; 328: 2327-2336

14) Beigel JH, Tomashek KM, Dodd LE et al. Remdesivir for the Treatment of Covid-19 — final Report. October 8, 2020 DOI: 10.1056/NEJMoa2007764

15) Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. New Engl J Med May 27, 2020 DOI: 10.1056/NEJMoa2015301

16) Spinner CD, Gottlieb RL, Criner GJ et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19. A randomized clinical trial .JAMA. Published online August 21, 2020. doi:10.1001/jama.2020.16349

29

17) Olender SA, Perez KK, Go AS, et al . Remdesivir for severe COVID-19 versus a cohort receiving standard of care. Clinical Infectious Diseases, ciaa1041, https://doi.org/10.1093/cid/ciaa1041 Published: 24 July 2020

18) WHO Solidarity trial consortium. Repurposed antiviral drugs for COVID-19 – interim WHO
SOLIDARITY trial results. medRxiv 2020. https://doi.org/10.1101/2020.10.15.20209817 posted Oct
15, 2020

19) Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: An open-label control study Engineering (Beijing). 2020;10.1016/j.eng.2020.03.007. doi:10.1016/j.eng.2020.03.007

20) Chen C, Huang J, Zhenshun Cheng Z, et al. Favipiravir versus Arbidol for COVID-19: A randomized clinical trial. medRxiv preprint doi: https://doi.org/10.1101/2020.03.17.20037432.this version posted March 20, 2020.

21) Preliminary Report of the Favipiravir Observational Study in Japan Favipiravir Observational Study Group. http://www.kansensho.or.jp/uploads/files/topics/ 2019ncov/ covid19_casereport_ en_200529.pdf Accessed 19 June 2020

22) Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for treatment of patients with moderate COVID-19: Interim results of a Phase II/III multicenter randomized clinical trial. Clinical Infectious Diseases, ciaa1176, https://doi.org/10.1093/cid/ciaa1176

23) Lagier JC, Million M, Gautret P, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. Travel Med Infect Dis. 2020 July-August; 36: 101791. Available on line 25 June 2020

24) Chen Z, Hu J,Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv preprint doi:https://doi.org/10.1101/2020.03.22.20040758.this version posted March 30, 2020.

25) Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19) J Zhejiang Univ (Med Sci) 2020, Vol. 49 Issue (1): 0-0 DOI: 10.3785/j.issn.1008-9292.2020.03.03

26) Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial. BMJ 2020;369:m1849

27) Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19. Med (2020), https://doi.org/10.1016/j.medj.2020.06.001

28) Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. New Engl J Med 2020 ;382(25):2411-2418

29) Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA 2020; 323(24): 2493-2502.

30) Mahévas M, Tran VT, Roumier M, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 2020;369:m1844

31) Ip A, Berry DA, Hansen E, et al, Hydroxychloroquine and tocilizumab therapy in COVID-19 patients - An observational study. PLoS ONE 15(8): e0237693.

32) Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Inf Dis. 2020 ; 97: 396–403

33) Cavalcanti AB. Zampieri FG, Rosa RG, et al .Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New Eng J Med published on line July 23, 2020 DOI: 10.1056/NEJ-Moa2019014

34) RECOVERY Collaborative Group. Effect of Hydroxychloroquine in hospitalized patients

with COVID-19. New Engl J Med October 8, 2020 DOI: 10.1056/NEJMoa2022926

40) Carlucci P, Tania Ahuja T, Petrilli CM, et al. Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients medRxiv doi: https://doi.org/10.1101/2020.05.02.20080036

41) Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med J 2020; 383:517-525

42) Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19.A randomized trial. Ann Int Med2020 Jul 16 : M20-4207

43) Mitjà O, Corbacho-Monné M, Ubals M, et al. Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial. Clinical Infectious Diseases, ciaa1009, <u>https://doi.org/10.1093/cid/ciaa1009</u> Published: 16 July 2020

44) Mitjà O, Ubals M, Corbacho-Monné M, et al. A cluster-randomized trial of hydroxychloroquine as prevention of Covid-19 transmission and disease. medRxiv 2020.07.20.20157651; doi: https://doi.org/10.1101/2020.07.20.20157651

45) Ferreira A, Oliveira-e-Silva A ,Bettencourt P. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection. J Med Virol 2020:1-5J Med Virol. 2020;1–5 DOI: 10.1002/jmv.26286

46) Abella BS, Jolkovsky EL, Biney BT, et al. Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers. A randomized clinical trial JAMAInternMed.doi:10.1001/jamainternmed.2020.6319 PublishedonlineSeptember30,2020.

47)) Li Y, Xie Z, Lin W, et al. An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI.Med (N Y). 2020 May 19 doi: 10.1016/j.medj.2020.04.001

48) Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir–Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787-1799.

49) RECOVERY Collaborative Group. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Published On-line October 5. 2020 https://doi.org/10.1016/ S0140-6736(20)32013-4.

50) Hung IFN , Lung KC, Tso EYK et al Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial Lancet,2020 May 30;395(10238):1695-1704.

51) Estebanez M, Ramirez-Olivencia G, Mata T, et al. Clinical evaluation of IFN beta-1-b in COVID-19 pneumonia: a retrospective study. MedRxiv doi: https://doi.org /10.1101/ 2020.05.15.20084293

52) Pereda R, González D, Rivero HB, et al. Therapeutic effectiveness of interferon-alpha 2b against COVID-19: the Cuban experience. medRxiv preprint doi: <u>https:// doi.org/10.1101/</u>2020.05.29.20109199.

53) PE Idelsis, Perez-Escribano J, Duncan-Robert Y, et al Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA medRxiv https://doi.org/10.1101/2020.07.29.20164251

54) Rahmani H, Davoudi-Monfared E,, Nourian A, et al. Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial. Int Immunopharmacol. 2020 Nov; 88: 106903. Published online 2020 Aug 24. doi: 10.1016/j.intimp.2020.106903

35

55) Meng Z, Wang T, Chen L, et al. An experimental trial of recombinant human interferon alpha nasal drops to prevent COVID-19 in medical staff in an epidemic area. medRxiv .https://doi.org/10.1101/2020.04.11.20061473

56) Bian H, Zheng ZH, Wei D. Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. medRxiv doi:https://doi.org/10.1101/ 2020.03.21.20040691

57) Xua X, Hanb M, Lia T, et al. Effective treatment of severe COVID-19 patients with tocilizumab 10970–10975 | Proc Natl Acad Sci | May 19, 2020 | vol. 117 | no. 20 www.pnas.org/cgi/doi/10.1073/ pnas.2005615117

58) Somers EC, Eschenauer GA, Troost JP. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. MedRxiv doi: https://doi.org/10.1101/2020.05.29.20117358

59) Rossi B, Nguyen LS, Zimmermann, et al. Effect of tocilizumab in hospitalized patients with severe pneumonia COVID-19: a cohort study medRxiv doi: https://doi.org/ 10.1101/2020.06.06.20122341

60) Martinez-Sanz J, Muriel A, l Ron R, et al. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: A Multicenter Cohort Study. MedRxiv doi: https://doi.org/ 10.1101/2020.06.08.20125245

61) Petrak R, Skorodin N, Van Hise N, et al. Tocilizumab as a therapeutic agent for critically ill patients infected with SARS-CoV-2. MedRxiv doi: https://doi.org/10.1101/ 2020.06.05.20122622

62) Perrone P, Piccirillo MC, Ascierto PA, et al. Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial. MedRXiv doi: https://doi.org/10.1101/2020.06.01.20119149

63) Garcia EM, Caballero VR, Albiach L, et al. Tocilizumab is associated with reduction of the risk of ICU admission and mortality in patients with SARS-CoV-2 infection medRxiv doi: https://doi.org/10.1101/2020.06.05.20113738

64) Wadud N, Ahmed N, Shergil M, et al. Improved survival outcome in SARs-CoV-2 (COVID-19) Acute Respiratory Distress Syndrome patients with Tocilizumab administration. MedRxiv doi: https:// doi.org/10.1101/2020.05.13.20100081

65) Sanchez-Montalva A, Selares-Nadal J, Espinosa-Pereiro J, et al. Early outcomes of tocilizumab in adults hospitalized with severe COVID19. An initial report from the Vall dHebron COVID19 prospective cohort study.doi: https://doi.org/10.1101/2020.05.07.20094599

66) Ramaswamy M, Mannam P, Comer R, et al. Off-label real world experience using tocilizumab for patients hospitalized with COVID-19 disease in a regional community health system: A case-control study medRxiv. doi: https://doi.org/10.1101/2020.05.14.20099234

67) Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2020; 2(8): 2, e474-e484

67) Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2020; 2: e325–31

68) Cauchois R, Koubia M, Delarbreb D, et al. Early IL-1 receptor blockade in severe inflammatoryrespiratory failure complicating COVID-19. Proc Nat Acad Sci 2020; 117: 18951-18953

69) Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol 2020; 2: e393-e400

70) Salvarani, C; Giovanni Dolci D, MD3; Marco Massari M et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia

JAMA Intern Med. Published online October 20, 2020. doi:10.1001/jamainternmed.2020.6615

71) Rosas IO, Bräu N,, Waters M, et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia posted September 12, 2020. medRxiv.https://doi.org/10.1101/2020.08.27.20183442doi:

72) Hermine O, Mariette X, Tharaux PL, et al .Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia. A randomized clinical trial Published Online: October 20, 2020. doi:10.1001/jamainternmed.2020.6820

73) Villar J, Ferrando C, Martínez D et al. Dexamethasone treatment for the acute respiratory distress syndrome: A multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267-276

74) RECOVERY Collaborative Group. Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report. July 17, 2020 DOI: 10.1056/NEJMoa2021436

75) Salton F, Confalonieri P, Santus P, et al. Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia. medRxiv preprint doi: https://doi.org/
10.1101/2020.06.17.20134031.this version posted June 25, 2020

76) Fadel R ,Morrison AR, Vahia A, et al. Early short-course corticosteroids in hospitalized patients with COVID-1. Clinical Infectious Diseases 2020; ciaa601, https://doi.org/10.1093/cid/ciaa601

77) Villar J, Confalonieri, M, Pastore, SM, et al. Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome caused by Coronavirus Disease 2019. Crit Care Explor April 2020;2 :e0111

78) Marik PE, Kory P, Varon J, et al. MATH+ protocol for the treatment of SARS-CoV-2 infection: the scientific rationale, Expert Review of Anti-infective Therapy https://doi.org/
10.1080/14787210.2020.1808462 published on line 18 aug 2020

79) Jeronimo CMP, Farias MEL, BSc, Val FFA, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): A randomised, double-blind, phase iib, placebo-con-trolled trial Clinical Infectious Diseases, ciaa1177, <u>https://doi.org/10.1093/cid/ciaa1177</u>

80) Dequin PF, Nicholas Heming NMD, PhD4,5; Mezian F, et a; Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19, A randomized clinical trial JAMA. 2020;324(13):1298-1306. doi:10.1001/jama.2020.16761

81) Chroboczek T, Lacoste L, Wackenheim C, et al. Beneficial effect of corticosteroids in severe
COVID-19 pneumonia: a propensity score matching analysis. MedRxiv: doi: https://doi.org/
10.1101/2020.05.08.20094755

82) Deftereos SG, Giannopoulos G, Dimitrios A, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with Coronavirus Disease 2019. The GRECCO-19 randomized clinical trial. JAMA Network Open. 2020;3:e2013136.

83) Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020 ;324(5):460-470.

84) Perotti C, Baldanti F, Bruno R, et al. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial.
Haematologica. 2020 Jul 23;haematol.2020.261784. doi: 10.3324/haematol.2020.261784

85) Avendano-Sola C, Ramos-Martinez A, Munez-Rubio E, et al. Convalescent Plasma for COVID19: A multicenter, randomized clinical trial. MedRxiv September 1, 2020. https://doi.org/
10.1101/2020.08.26.20182444doi:

86) Joyner MJ, Klassen SA, Senefeld JW, et al. ,Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy. MedRxiv posted August 28, 2020.https://doi.org/
10.1101/2020.07.29.20162917doi: medRxiv pr

87) Joyner MJ, Bruno KA, Klassen SA, et al, Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients Mayo Clin Proc. 2020;95 (9):1888-1897

88) Agarwal A, Mukherjee A, Kumar g, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) s: BMJ 2020;371:m3939 http://dx.doi.org/10.1136/bmj.m3939

89) Freedberg DE, Conigliaro J, Sobieszczyk ME, et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study. Gastroenterology. 2020 May 22 doi: 10.1053/j.gastro.2020.05.053 [Epub ahead of print]

90) Rajter JC, Sherman M, Fatteh N, et al. ICON (Ivermectin in COvid Nineteen) study: Use of ivermectin is associated with lower mortality in hospitalized patients with COVID19. medRxiv doi: https:// doi.org/10.1101/2020.06.06.20124461

42

91) Folegatti PM, J Ewer KJ, Parvinder K Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 ;396(10249):467-478

92) Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 —preliminary report N Engl J Med. 2020 Jul 14;NEJMoa2022483.

doi: 10.1056/NEJMoa2022483

93) Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo controlled, phase 2 trial. Lancet 2020; 395(10240):, P1845-1854, June 13, 2020

94) Keech C, Albert G, Cho I, et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine..New Engl J Med. DOI: 10.1056/NEJMoa2026920

95) Xia S, Duan K, Yuntao Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes. Interim analysis of 2 randomized clinical trials. JAMA 2020 ;e2015543.doi: 10.1001/jama.2020.15543

96) Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. Published online September 4, 2020 https://doi.org/10.1016/S0140-6736(20)31866-31

97) Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report. [published online ahead of print August 12, 2020] Nature 2020

98) Liu M, Thomadsen R, Yao S. Forecasting the spread of COVID-19 under different reopening strategies. medRxiv preprint doi: https://doi.org/10.1101/2020.05.26.20113993

99) Institute for Health Metrics and Evaluation. COVID-9 projections . Covid 19.healthdata.org

100) Marik PE, Varon J, Kory P. Treatment of Covid-19 is critically phase specific. Crit Care Shock 2020;23 :10-12

101) Wan Y, Shang J, Sun S, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol 2020;94:e02015-19.

44

102) Fatima K, Syed NI. Dengvaxia controversy: impact on vaccine hesitancy. J Glob Health. 2018;8(2): 020312.

103) Edridge AWD, Kaczorowska J, Hoste ACR et al. Coronavirus protective immunity is short-lasting.medRxiv preprint doi: https://doi.org/10.1101/2020.05.11.20086439.this version posted June 16, 2020.

104) Sepkowitz KA. AIDS-The first 20 years. N Engl J Med 2001; 344 (23):1764-1772

105) Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 2010; 85(1): 1-18

106) Fauci AS. Preface: Evolving ethical issues over the course of the AIDS pandemic. Public Health Rev 34, 2 (2012)

107) Harris NS, Johnson AS, Huang YA, et al. Vital Signs: Status of human immunodeficiency virus testing, viral suppression, and HIV pre-exposure prophylaxis - United States, 2013-2018. MMWR Morb Mortal Wkly Rep. 2019; 68 (11):1117-1123

TABLE 1. PUBLISHED STUDIES AS OF NOVEMBER 1, 2020. Each agent is listed along with the country originating the publication. The type of control procedure: RCT: Randomized controlled study PLAC: Placebo, soc: standard of care which is variable depending on each location. AC: Active control: the control options are listed in parenthesis. OBS: retrospective observation study. LPV/R: lopanovir/ritonavir; HCQ: hydroxychloroquine; AZM: azithromycin; IFN: interferon; tocilizumab: TCZ. SEV: severe; CRIT: critical; MOD: moderate. W.H.O.: World Health Organization

TREATMENT	LOCATION	TYPE OF CONTROL	NUMBER SUBJECTS	SETTING	SEVERITY	RESULTS
Remdesivir ¹²	China	RCTPLAC vs soc	273	HOSP	SEV	mortality in remdesivir group 14%, control 13% 11% in remdesivir group with <10 days symptoms Vs 14% in placebo group, no difference in viral clearance
Remdesivir ¹³	U.S.A.	OBS.	53	HOSP	SEV,CRIT	Mortality 18% (6 of 34 patients on mechanical ventilation 5% 1 of 19 of those not receiving mechanical ventilation
Remdesivir ¹⁴	U.S.A.	RCTPLAC	1062	HOSP	SEV,CRIT	29 day mortality 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03)
Remdesivir ¹⁵	U.S.A.	AC(5 day vs 10 day, no control)	397	HOSP	MOD,SEV	10 day group had more severe disease, mortality 8% in 5 day group 11% in 10 day group
Remdesivir ¹⁶	U.S.A.	AC(5 day vs 10 day, vs soc)	596	HOSP	MOD	Improved clinical status in 5 day group but not in10 day group
Remdesivir ¹⁸	W.H.O.	AC(10 day, vs soc)	5451	HOSP	MOD,SEV	Mortality Remdesivir RR=0.95 (0.81-1.11, p=0.50 301/2743 active vs 303/2708 control

(Favipiravir) FVP ¹⁹	China	AC(lpv/r vs favipiravir)	70	HOSP	MOD,SEV	4 day viral clearance time FPV vs 11 days lpv/r
						CT scan improvement 92% fvp vs 62% lpv/r
FVP ²⁰	China	AC (umifenovir vs favipiravir)	240	HOSP	MOD,SEV	Clinical recovery rate 56%umifenovir vs 71% fvp time to fever reduction and cough shorter fvp
FVP ²¹	Japan	OBS (no control)	1918	HOSP	MOD,SEV,CRIT	Mortality 11.6% at one month
FVP ²²	Russia	AC (vs soc)	60	HOSP	MOD	viral clearance achieved in 25/40 (62.5%) patients on fvp vs 6/20 (30.0%) patients on SOC (p=0.018)
HCQ ²³	France	OBS(hcq+azm, noncomparable control group)	3737	MIXED	MILD,MOD	0.9% overall mortality, no sudden death, no cardiac arrythmias
HCQ ²⁴	China	RCT(soc)	62	HOSP	MOD	shorter time to temperature recovery Pneumonia improvement 81% (HCQ) vs 55% soc no progression to severe status any HCQ patient versus 4 of 17 (soc)
HCQ ²⁵	China	RCT(soc)	30	HOSP	MOD	no differences in viral clearance time
HCQ ²⁶	China	RCT(hcq vs soc)	150	HOSP	MILD,MOD	No difference in viral clearance at 28 days
HCQ ²⁷	U.S.A.	OBS(hcq vs no hcq)	338	HOSP	MOD,SEV	Mortality twice as high in patients chosen for HCQ treatment

HCQ ²⁸	U.S.A.	OBS (hcq vs no hcq)	1376	HOSP	MOD,SEV	no significant association between HCQ use and intubation or death
						(hazard ratio, 1.04, 95% confidence interval, 0.82 to 1.32).
						HCQ treated patients were sicker with ppO2 223 vs 360 for controls
						still lower than controls after propensity score matching 223 vs 273
HCQ ²⁹	U.S.A.	OBS (hcq+azt vs hcq vs azt)	1438	HOSP	MOD,SEV	Overall in-hospital mortality was 20.3%,25.7% hcq+azt, 19.9% hcq alone
		ney vs azij				neither drug 17.7%, cardiac arrest more likely with hcq+azt
HCQ ³⁰	France	OBS (hcq vs no hcq)	181	HOSP	MOD,SEV	no difference in mortality or need to transfer to ICU
						30-day unadjusted mortality for patients
HCQ ³¹	U.S.A.	OBS (hcq vs hcq plus azm, azm	1914	HOSP	MOD,SEV	receiving hydroxychloroquine alone, azithromycin alone, the combination or neither drug was 25%, 20%, 18%, and 20%,
						Overall mortality was 18.1% (95% CI:16.6%-19.7%); by treatment: hcq+azt,
HCQ ³²	U.S.A.	OBS (hcq vs	2541	HOSP	MOD,SEV	(20.1% [95% CI: 17.3%-23.0%]), hcq alone, (13.5% [95% CI:
iiida	0.0	hcq plus azm, azm	2012			11.6%-15.5%]), azt alone,(22.4% [95% CI: 16.0%-30.1%]), neither drug, (26.4%
						[95% CI: 22.2%-31.0%]).
HCQ ³⁸	Brazil	RCT (hcq+azm, hcq, vs soc)	504	HOSP	MILD,MOD	No difference in clinical status of patients or mortality at 15 days
		vo 300 <i>j</i>				mortanty at 15 days
HCQ ³⁹	U.K.	RCT (hcq vs soc)	1542	HOSP	MOD,SEV	no significant difference in28-day mortality (26.8% hydroxychloroquine vs. 25% usual care;

HCQ ²³	W.H.O.	AC(vs soc)	1853	HOSP	MOD,SEV	Mortality RR=1.19 (0.89-1.59, p=0.23; 104/947 HCQ vs 84/906 control
HCQ ⁴⁰	U.S.A.	OBS (hcq+azt +zinc vs hzq +azt)	932	HOSP	MOD,SEV	Reduction in mortality with addition of zinc OR 0.449, 95% CI 0.271-0.744).
HCQ ⁴¹	U.S.A.	RCTPLAC	821	OUTPAT	HEALTHY	No significant difference in incidence of subsequent COVID-19 infection (11.8% HCQ, 14.3% PLAC, p=0.35)
HCQ ⁴²	U.S.A.	RCTPLAC	423	OUTPAT	MILD	At 14 days, 24% (49 of 201) of participants receiving hydroxychloroquine had ongoing symptoms compared with 30% (59 of 194) receiving placebo (P = 0.21)
HCQ ²³	W.H.O.	AC(10 day, vs soc)	5042	HOSP	MOD,SEV	Mortality HCQ RR=1.19 (0.89-1.59, p=0.23; 104/947 vs 84/906
HCQ ⁴³	Spain	RCTPLAC	293	OUTPAT	MILD	no difference in viral load at 7 days after 6 days HCQ treatment nor risk of hospitalization compared to untreated patients

HCQ ⁴⁴	Spain	RCTPLAC	2324	OUTPAT	HEALTHY	no significant difference in the primary outcome of PCR-confirmed, symptomatic Covid-19 disease (6.2% usual care vs. 5.7% HCQ; risk ratio 0.89 [95% confidence interval 0.54-1.46]), nor evidence of prevention of SARS-CoV-2 transmission (17.8% usual care vs. 18.7% HCQ)
HCQ ⁴⁵	Portugal	OBS(HCQ vs no HCQ)	1293	OUTPAT	HEALTHY	odds ratio of SARS-CoV-2 infection for chronic treatment with HCQ 0.51 (0.37-0.70).
HCQ ⁴⁶	U.S.A.	RCTPLAC	132	OUTPAT	HEALTHY	2 month treatment with HCQ in hospital workers no significant difference in SARS- Cov-2 infection rate HCQ 6.3% vs placebo 6.6%
LPV/r ⁴⁷	China	AC(lpv/r vs umifenovir vs no antiviral)	44	HOSP	MOD,SEV	No differences in viral load, clinical status, or CT scan
LPV/r ⁴⁸	China	RCT(soc)	199	HOSP	SEV	No differences in mortality, viral load; time to clinical improvement 1 day less in lpv/r group
LPV/r ⁴⁹	U.K.	RCT(soc)	1596	HOSP	MOD,SEV	no significant difference in the primary endpoint of 28-day mortality (22.1% LPV/r vs. 21.3% usual care; relative risk 1.04 [95% confidence interval 0.91-1.18];(p=0.58)
LPV/r ²³	W.H.O.	AC(LPV/r vs soc)	2771	HOSP	MOD,SEV	Mortality LPV/r (RR=1.00 (0.79- 1.25, p=0.97; 148/1399 vs 146/1372

LPV/r ⁵⁰	Hong Kong	AC(lpv/r+ribavirin+beta interferon vs lpv/r+ribavirin)	2772	HOSP	MOD.SEV	Triple combination of interferon beta-1b, lpv/r, and ribavirin yielded more rapid viral clearance but attributable primarily to interferon
IFN- β-1a ⁵¹	Cuba	OBS	761	HOSP	MIXED	Case fatality ratio 0.92 for interferon treated patients
IFN-α-2b ⁵²	Cuba	AC(RCT (IFN- α-2b- vs IFN-α-2b + IFN- γ, background LPV/R +chloroquine)	66	HOSP	MIXED	Time to reach the elimination of Viral clearance 3 days for combined interferons vs 5 days for IFN- α-2b alone (p=0.0027
IFN- β-1a ⁶³	Iran	RCT (IFN- β-1a vs soc)	81	HOSP	SEV,CRIT	28-day overall mortality significantly lower in the IFN then the control group (19% vs. 43.6% respectively, p= 0.015). Early administration significantly reduced mortality (OR=13.5; 95% CI: 1.5-118)
IFN ²³	W.H.O.	AC(vs soc)	4100	HOSP	MOD,SEV	Mortality IFNRR=1.16 (0.96-1.39, p=0.11; 243/2050 vs 216/2050)
IFN-α nasal drops ⁵⁴	China	OBS	2944	OUTPAT	HEALTHY	No cases of COVID-19 compared to historical control
Meplazumab ⁵⁵	China	RCT(soc)	38	HOSP	MOD,SEV	Viral clearance 3 days (1.5-4.5) compared to 13 days(6.5-19.5) in control group
Tocilizumab(TCZ) ⁵⁶	China	OBS(no control)	20	HOSP	SEV,CRIT	no patient died, rapid defervescence,

improvement in oxygenation

TCZ ³⁶	U.S.A.	OBS (TCZ vs soc)	1914	HOSP	CRIT	30 day unadjusted mortality with and without TCZ of 46% versus 56%
TCZ ⁵⁷	U.S.A.	OBS (TCZ vs soc)	154	HOSP	CRIT	TCZ was associated with a 45% reduction in hazard of death [hazard ratio 0.55 (95% CI 0.33, 0.90)]
TCZ ⁵⁸	France	Matched cohort (TCZ vs soc)	168	HOSP	SEV	TCZ was associated with a 51% reduction in composite of death and mechanical ventilation(HR)=0.49 (95% confidence interval (95CI)=0.3-0.81), p-value=0.005)
TCZ ⁵⁹	Spain	OBS	1229	HOSP	SEV	TCZ associated with decreased risk of death (aHR 0.34, 95% CI 0.16 to 0.72, p=0.005) and ICU admission or death (aHR 0.38, 95% CI 0.19 to 0.81, p=0.011) among patients with baseline CRP >150 mg/L,
TCZ ⁶⁰	U.S.A.	OBS (TCZ early vs late treatment))	154	HOSP	CRIT	increased survival and avoidance mechanical ventilation with early treatment
TCZ ⁶¹	Italy	OBS	1221	HOSP	SEV	15.6% moratility at 14 days, 20% at 30 days in TCZ treated patients
TCZ ⁶²	Spain	OBS(TCZ vs soc)	171	HOSP	MOD,SEV	TCZ associated with decreased risk OF ICU admission (10.3% vs. 27.6%, P= 0.005) and

need of invasive ventilation (0 vs 13.8%, P=0.001)

TCZ ⁶³	U.S.A.	OBS (TCZ vs soc)	94	HOSP	CRIT	Survival rate 48 % in the control group and 61% in patients who received TCZ P < 0.00001.
TCZ ⁶⁴	Spain	OBS(TCZ vs soc)	82	HOSP	CRIT	7 day mortality with TCZ 26.8%. Age adjusted HR 2.1 if TCZ begun after onset of respiratory failure
TCZ ⁶⁵	U.S.A.	OBS (TCZ vs soc)	86	HOSP	SEV	Reduced risk of death in patients who received TCZ (RR 0.472; 95% CI 0.449-0.497 P < 0.00001)
TCZ ⁶⁶	Italy	OBS(TCZ vs soc)	544	HOSP	SEV	TCZ treatment was associated with a reduced risk of invasive mechanical ventilation or death (adjusted hazard ratio 0.61, 95% CI 0.40–0.92; p=0.020).
Anakinra ⁶⁵	Italy	OBS(vs soc)	45	HOSP	SEV	At 21 days, survival 90% in the high-dose anakinra group vs 56% in soc group (p=0·009). Mechanical ventilation-free survival 72% in the anakinra group vs 50% in soc group (p=0·15).
Anakinra ⁶⁶	France	OBS(vs soc)	22	HOSP	SEV	12 anakinra treated patients showed greater clinical improvement and decreased cytokine levels

Anakinra ⁶⁷	France	OBS(vs soc)	96	HOSP	SEV	Admission to the ICU for invasive mechanical ventilation or death occurred in 13 (25%) patients in the anakinra group and 32 (73%) patients in the historical group (hazard ratio [HR] 0.22 [95% CI 0.11–0.41; p<0.0001).
TCZ ⁷⁰	Italy	RCTPLAC(TCZ vs soc)	126	HOSP	SEV	No difference in worsening of clinical state day 28(28.3% TCZ, 27% PLAC)
TCZ ⁷¹	U.S.A.	RCTPLAC(TCZvs soc)	452	HOSP	SEV,CRIT	No difference in mortality day 28(19.7% TCZ, 19.4% PLAC)
TCZ ⁷²	France	RCT(TCZ vs soc)	130	HOSP	SEV	HR for mechanical ventilation or death at day 14 0.58 (90% Crl, 0.30 to 1.09). day 28 mortality 11.1% TCZ, 11.9% soc (adjusted HR, 0.92; 95% Cl 0.33-2.53).


Dexamethasone ⁷⁴	U.K.	RCT(soc)	6119	HOSP	MOD,SEV	Dexamethasone reduced 28-day mortality by 35% in patients receiving invasive mechanical ventilation (rate ratio 0.65 [95% CI 0.51 to 0.82]; p<0.001) and by 20% in patients receiving oxygen without invasive mechanical ventilation (rate ratio 0.80 [95% CI 0.70 to 0.92]; p=0.002
Methylprednisolone ⁷⁵	Italy	RCT(soc)	173	HOSP	SEV	Mehtylprednisoloong group had fewer deaths (6 vs. 21, adjusted HR=0.29; 95% CI: 0.12-0.73) and more days off invasive MV (24.0 plus-or-minus sign 9.0 vs. 17.5 plus-or-minus sign 12.8; p=0.001)

Methylprednisolone ⁷⁶	U.S.A.	OBS(soc)	213	HOSP	SEV	Early short course of methylprednisolone resulted in decrease need for ICU care, mechanical ventilation and mortality ((34.9% vs 54.3%, P = .005)
Methylprednisolone ⁷⁹	Brazil	RCT(soc)	393	HOSP	MOD,SEV	Overall 28-day mortality was 76/199 (38.2%) in the placebo group vs 72/194 (37.1%) in group which received methylprednisolone short 5 day curse (P=0.629)
Corticosteroid ⁸⁰	France	OBS(vs no steroid)	70	HOSP	MOD,SEV	Reduced risk of intubation -47.1% (95% confidence interval -71.8% to -22.5%).
Hydrocortisone ⁸¹	France	RCT(soc)	149	HOSP	CRIT	Treatment failure in hydrocortisone group 42% vs 51% placebo
Colchicine ⁸²	Greece	RCT(colchicine vs soc)	105	HOSP	MOD,SEV	The clinical primary end point rate was 14.0% in the control group (7 of 50 patients) and 1.8%in the colchicine group (1 of 55 patients) (odds ratio, 0.11; 95%CI, 0.01-0.96; P = .02).
Convalescent plasma ⁸³	China	RCT(soc)	103	HOSP	SEV.CRIT	time to clinical improvement at 28 days was 4.9 days shorter (95% CI, -9.33 to -0.54 days) in convalescent plasma group (HR, 2.15 [95% CI, 1.07-4.32]; P = .03). No significant difference in critically ill patients. Mortality 28-day mortality (15.7% convalescent plasma vs 24.0% control ; P = .30)

Convalescent plasma ⁸⁴	Italy	OBS	46	HOSP	CRIT	7 day mortality 6.5%
Convalescent plasma ⁸⁵	Spain	RCT(soc)	81	HOSP	MOD,SEV	Mortality 0% for conv plasma group vs 9.3% for control at 29
Convalescent plasma ⁸⁶	U.S.A.	OBS	21,987	HOSP	MOD,SEV	7 day mortality 13%
Convalescent plasma ⁸⁷	U.S.A.	OBS	3,082	HOSP	MOD,SEV	adjusted 30-351 day mortality was 30% in patients treated with plasma with low antibody levels (IgG) 4 352 or more days after COVID-19 diagnosis. By contrast 30- day mortality was 20% in 353 patients treated within 3 days of diagnosis with plasma with high antibody levels.
Convalescent plasma ⁸⁸	India	RCT(soc)	464	HOSP	MOD, SEV	Progression to severe disease or all cause mortality at 28 days after enrolment occurred in 44 (19%) participants in the intervention arm and 41 (18%) in the control arm (risk difference 0.008 (95% confidence interval –0.062 to 0.078); risk ratio 1.04, 95% confidence interval 0.71 to 1.54).
Famotidine ⁸⁹	U.S.A.	OBS(famotidine vs soc)	1620	HOSP	MOD,SEV	HR for famotidine for death or intubation 0.43, 95% CI (0.21-0.88)
Ivermectin ⁹⁰	U.S.A.	OBS(ivermectin vs soc)	280	HOSP	MOD,SEV	lower mortality in the ivermectin group (25.2% versus 15.0%, OR 0.52, 95% CI 0.29-0.96, P=.03)

ChAdOx1- nCoV19 ⁹¹	U.K.	RCT (plac)	1077	OUTPAT	HEALTHY	100% spike protein neutralising antibody, spike specific T cell responses
mRNA1273 ⁹²	U.S.A.	RCT(plac)	45	OUTPAT	HEALTHY	High neutralising antibody titiers, positive Th1-CD4 response
Ad5 vectored Covid Vaccine ⁹³	China	RCT(plac)	603	OUTPAT	HEALTHY	Significant neutralizing antibody titers and positive T cell response
NVX-Cov2373 ⁹⁴	Australia	RCT(plac)	134	OUTPAT	HEALTHY	Significant neutralizing antibody titers and positive T cell response
Coronavac ⁹⁵	China	RCT(plac)	330	OUTPAT	HEALTHY	Significant neutralizing antibody titers and positive T cell response
Ad5 and Ad26 vectored Covid Vaccines ⁹⁶	Russia	OBS	76	OUTPAT	HEALTHY	Significant neutralizing antibody titers and positive T cell response
BTN162b1 and b2 ⁹⁷	U.S.A.	RCT(plac)	195	OUTPAT	HEALTHY	high titer, broad serum neutralizing responses, TH1 phenotype CD4+ T helper cell responses, and strong interferon γ (IFNγ) and interleukin-2 (IL-2) producing CD8+ cytotoxic T-cell responses

(a)



(b)




Figure 1: THE PHASES OF COVID-19 INFECTION. Asymptomatic viremia typically lasts for 5 days followed by symptoms of an upper respiratory infection. The immune response takes hold over the next week. Pneumonic infiltrates begin to appear. In patients destined for severe infection, a hyperinflammatory reaction takes hold, leading to worsening of pulmonary symptoms, hypoxia, and potentially acute respiratory distress syndrome.

TRIAL REGISTRATION	COUNTRY	PROJECTED DATE	SUBJECTS	AGENTS STUDIED	NUMBER
		CLOSE			
		ENROLLMENT			SUBJECTS
CHICTR2000030946	China	2020-Apr	HOSP	Anticoagulants, Other	120
CHICTR2000029898	China	2020-Apr	HOSP	HCQ	100
NCT04282902	China	2020-Apr	HOSP	pirfenidone	294
CHICTR2000030179	China	2020-Apr	HOSP	Plasma based therapy, SOC	100
CHICTR2000030545	China	2020-Apr	HOSP	SOC, Herbal tea	300
NCT04480593	Brazil	2020-Aug	HOSP	Alternative therapy, SOC	120
NCT04335552	United States	2020-Aug	HOSP	AZM, HCQ, SOC	500
NCT04355637	Spain	2020-Aug	HOSP	Corticosteroids, SOC	300
NCT04349592	Qatar	2020-Aug	HOSP	HCQ, HCQ + AZM, SOC	456
NCT04347031	Russia	2020-Aug	HOSP	HCQ, Other, TCZ +AZM	320
NCT04394442	Saudi Arabia	2020-Aug	HOSP	HCQ, SOC	200
NCT04420247	Brazil	2020-Aug	HOSP	HCQ, SOC	100
NCT04476888	Pakistan	2020-Aug	HOSP	Plasma based therapy, SOC	100
NCT04349098	United States	2020-Aug	HOSP	selinexor, SOC	230
NCT04326426	United States	2020-Aug	HOSP	Tradipitant (neurokinin 1 inhibitor),SOC	300
NCT04445272	Spain	2020-Aug	HOSP	TCZ	500
NCT04311697	United States	2020-Aug	HOSP	aviptadil Inhaled solution, SOC	144
NCT04381858	Mexico	2020-Aug	HOSP	Igs, Plasma based therapy	500
				Non-invasive respiratory support, Positioning + Non-invasive	
NCT04325906	United States	2020-Aug	HOSP	respiratory support	346
NCT04394377	Brazil	2020-Dec	HOSP	Anticoagulants	600
NCT04351724	Austria	2020-Dec	HOSP	Anticoagulants, HCQ, LPV/r, mAb, RAS blockade, SOC	500
				Antiretroviral + Dexamethasone, Other, Other + Antiretroviral, Other	
NCT04452565	United States	2020-Dec	HOSP	+ Dexamethasone	525
NCT04396106	United States	2020-Dec	HOSP	AT-527 RNA polymerase inhbitor	190
NCT04365699	United States	2020-Dec	HOSP	AT001, SOC	500
NCT04321096	Denmark	2020-Dec	HOSP	Camostat, SOC	580

NCT04392531	Spain	2020-Dec	HOSP	Cyclosporine, SOC	120
NCT04397718	United States	2020-Dec	HOSP	Hormone therapy, SOC	198
NCT04421027	United States	2020-Dec	HOSP	JAKi, SOC	600
NCT04469114	Israel	2020-Dec	HOSP	JAKi, SOC	260
NCT04347239	United States	2020-Dec	HOSP	Leronlimab, SOC	390
NCT04376684	United States	2020-Dec	HOSP	mAb, SOC	800
NCT04401202	Saudi Arabia	2020-Dec	HOSP	Nigella sativa, SOC	200
NCT04432298	United States	2020-Dec	HOSP	pamrevlumab (Ab to connective tisue growth factor), SOC	130
NCT04433546	United States	2020-Dec	HOSP	pemziviptadil, SOC	210
NCT04392232	United States	2020-Dec	HOSP	Plasma based therapy	100
NCT04400058	United States	2020-Dec	HOSP	Plasma based therapy, SOC	208
NCT04359810	United States	2020-Dec	HOSP	Plasma based therapy, SOC	105
NCT04424797	United States	2020-Dec	HOSP	Positioning	100
NCT04391140	Spain	2020-Dec	HOSP	Positioning + Respiratory support, Respiratory support	248
NCT04402879	Canada	2020-Dec	HOSP	Positioning, SOC	596
NCT04365257	United States	2020-Dec	HOSP	prazosin, SOC	220
NCT04412356	Sweden	2020-Dec	HOSP	Procedure	180
NCT04479358	United States	2020-Dec	HOSP	SOC, TCZ	332
NCT04317092	Italy	2020-Dec	HOSP	TCZ	400
NCT04433910	Germany	2020-Dec	HOSP	Plasma based therapy, SOC	106
NCT04433910	Germany	2020-Dec	HOSP	Plasma based therapy, SOC	106
NCT04406389	United States	2020-Dec	HOSP	Anticoagulants	186
NCT04344730	France	2020-Dec	HOSP	Dexamethasone with or without respiratory suppport, SOC	550
NCT04480424	United States	2020-Dec	HOSP	Ivlg, SOC	100
NCT04443881	Spain	2020-Dec	HOSP	Anakinra, SOC	180
				Anticoagulants, Anticoagulants + Corticosteroids, Corticosteroids,	
NCT04485429	Brazil	2020-Dec	HOSP	SOC	268
NCT04466670	Brazil	2020-Dec	HOSP	Anticoagulants, Antihypertensive	310
NCT04409509	United States	2020-Dec	HOSP	FX12 antbody, SOC	124
NCT04535063	Argentina	2020-Dec	HOSP	Plasma based therapy	200
NCT04336462	China	2020-Feb	HOSP	Hydrogen, oxygen, SOC	100

CHICTR2000032367	China	2020-Jul	HOSP
NCT04355897	United States	2020-Jul	HOSP
NCT04342182	Netherlands	2020-Jul	HOSP
NCT04345523	Spain	2020-Jul	HOSP
NCT04468646	Pakistan	2020-Jul	HOSP
CHICTR2000030333	China	2020-Jul	HOSP
NCT04459325	Russia	2020-Jul	HOSP
NCT04322344	Italy	2020-Jun	HOSP
NCT04305106	China	2020-Jun	HOSP
NCT04375202	Italy	2020-Jun	HOSP
NCT04347980	France	2020-Jun	HOSP
CHICTR2000029777	China	2020-Jun	HOSP
CHICTR2000029781	China	2020-Jun	HOSP
CHICTR2000034796	China	2020-Mar	HOSP
NCT04329195	France	2020-May	HOSP
NCT04329650	Spain	2020-May	HOSP
CHICTR2000030894	China	2020-May	HOSP
CHICTR2000029603	China	2020-May	HOSP
CHICTR2000030001	China	2020-May	HOSP
CHICTR2000029763	China	2020-May	HOSP
CHICTR2000029755	China	2020-May	HOSP
CHICTR2000029765	China	2020-May	HOSP
CHICTR2000030779	China	2020-May	HOSP
NCT04310228	China	2020-May	HOSP
NCT04346199	Argentina	2020-Nov	HOSP
NCT04444700	Brazil	2020-Nov	HOSP
NCT04362085	Canada	2020-Nov	HOSP
NCT04344288	France	2020-Nov	HOSP
NCT04382053	Brazil	2020-Nov	HOSP
NCT04358081	United States	2020-Nov	HOSP
NCT04362137	United States	2020-Nov	HOSP

Exercise, SOC	186
Plasma based therapy	100
Plasma based therapy, SOC	426
Plasma based therapy, SOC	278
Neurokinin 1 receptor agonist, SOC	100
pirfenidone, SOC	292
dornase, alfa	100
Alternative therapy, SOC	120
Bevacizumab, SOC	140
Colchicine, SOC	308
Dexamethasone + HCQ, HCQ	122
SOC, Herbal tea	160
SOC, Herbal tea	160
Anticoagulants, SOC	160
Antihypertensive	554
Corticosteroids, Siltuximab	200
FPV, FPV + TCZ, TCZ	150
LPV/r, ASC09/r	160
LPV/r, Emcetrabine/r, SOC	240
SOC, Heral Tea	408
SOC, Herbal tea	120
SOC, TCZ	188
ulinastatin, SOC	100
FPV, FPV + TCZ, TCZ	150
Acalabrutinib, SOC	140
Anticoagulants, SOC	462
Anticoagulants, SOC	462
Corticosteroids, SOC	304
DFV890, SOC	120
HCQ, HCQ + AZM, SOC	444
JAKi, SOC	402

NCT04511819	United States	2020-Nov	HOSP
NCT04448756	United States	2020-Nov	HOSP
NCT04441385	Spain	2020-Nov	HOSP
NCT04463420	Iran	2020-Nov	HOSP
NCT04388410	Mexico	2020-Nov	HOSP
NCT04495101	Spain	2020-Nov	HOSP
NCT04449718	Brazil	2020-Nov	HOSP
NCT04386850	Iran	2020-Nov	HOSP
NCT04384900	Denmark	2020-Nov	HOSP
NCT04400890	United States	2020-Nov	HOSP
NCT04477655	Mexico	2020-Nov	HOSP
NCT04427098	Italy	2020-Oct	HOSP
NCT04530578	Argentina	2020-Oct	HOSP
NCT04486508	Iran	2020-Oct	HOSP
NCT04470622	United States	2020-Oct	HOSP
NCT04340557	United States	2020-Oct	HOSP
NCT04364893	Brazil	2020-Oct	HOSP
NCT04350320	Spain	2020-Oct	HOSP
NCT04322396	Denmark	2020-Oct	HOSP
NCT04348656	United States	2020-Oct	HOSP
NCT04385043	Italy	2020-Oct	HOSP
NCT04395144	Canada	2020-Oct	HOSP
NCT04335071	Switzerland	2020-Oct	HOSP
NCT04385836	Saudi Arabia	2020-Sep	HOSP
NCT04341116	United States	2020-Sep	HOSP
NCT04335136	Austria	2020-Sep	HOSP
NCT04386616	United States	2020-Sep	HOSP
NCT04452435	India	2020-Sep	HOSP
NCT04451174	Chile	2020-Sep	HOSP
NCT04332094	Spain	2020-Sep	HOSP
NCT04403100	Brazil	2020-Sep	HOSP

Losmapimod, SOC	410
M5049 (toll like receptor inhibitor), Other	150
Maraviroc, SOC	200
PHR160 asal spray+ HCQ + NSAIDs + AZM	224
Plasma based therapy, SOC	410
prolastin (proteinase inhibitor), SOC	100
SOC, Vitamin D	200
SOC, Vitamins	1500
Positioning	150
Plant polyphenols	200
Positioning, SOC	200
Anticoagulants	300
Anticoagulants	200
Anticoagulants, SOC, Statins	600
Aprepitant (antiemetic), SOC	100
ARB, SOC	200
ARBs + ACEi, SOC	700
Colchicine, SOC	102
HCQ + AZM, SOC	226
Plasma based therapy, SOC	1200
Plasma based therapy, SOC	400
Positioning, SOC	346
SOC, TCZ	100
alpha1 antitrypsin, SOC	150
anti GM-CSF, SOC	144
Antihypertensive, SOC	200
astegolimab, SOC	300
C21, SOC	100
Corticosteroids, SOC	184
HCQ + AZM, TCZ + AZM + HCQ	276
HCQ, HCQ + LPV/r, LPV/r, SOC	1968

NCT04370262	United States	2020-Sep	HOSP	
NCT04351152	United States	2020-Sep	HOSP	
NCT04334629	United Kingdom	2020-Sep	HOSP	
NCT04374526	Italy	2020-Sep	HOSP	
CHICTR2000030522	China	2020-Sep	HOSP	
NCT04379271	Bulgaria	2020-Sep	HOSP	
NCT04377620	United States	2020-Sep	HOSP	
NCT04445935	Qatar	2020-Sep	HOSP	
NCT04359277	United States	2021-Apr	HOSP	
NCT04360824	United States	2021-Apr	HOSP	
NCT04360824	United States	2021-Apr	HOSP	
NCT04312009	United States	2021-Apr	HOSP	
NCT04381377	Russia	2021-Apr	HOSP	
NCT04367168	Mexico	2021-Apr	HOSP	
IRCT20200517047485N1	Iran	2021-Apr	HOSP	
NCT04328493	Vietnam	2021-Apr	HOSP	
NCT04328493	Vietnam	2021-Apr	HOSP	
NCT04320056	Canada	2021-Apr	HOSP	
NCT04344431	France	2021-Apr	HOSP	
NCT04362176	United States	2021-Apr	HOSP	
NCT04359797	United States	2021-Apr	HOSP	
NCT04346615	United States	2021-Apr	HOSP	
NCT04352751	Pakistan	2021-Apr	HOSP	
IRCT20200414047072N1	Iran	2021-Apr	HOSP	
NCT04389710	United States	2021-Apr	HOSP	
NCT04355143	United States	2021-Apr	HOSP	
NCT04387760	Bahrain	2021-Apr	HOSP	
CHICTR2000029739	China	2021-Aug	HOSP	
NCT04513158	United States	2021-Aug	HOSP	
NCT04345692	United States	2021-Dec	HOSP	
NCT04381936	United Kingdom	2021-Dec	HOSP	

HCQ, HCQ + Other, SOC	942
Lenzilumab, SOC	300
NSAIDs, SOC	230
Plasma based therapy, SOC	182
SOC, Herbal tea	100
vidofludimus (pyrimidine synthesis inhibitor), SC	230
JAKi, SOC	500
Anticoagulants, SOC	100
Anticoagulants	1000
Anticoagulants	170
Anticoagulants	170
ARBs	200
Azoximer bromide, SOC	394
Colchicine, SOC	174
HCQ + Atazanavir/ritonavir, HCQ + LPV/r	108
HCQ, SOC	250
HCQ, SOC	250
Non-invasive respiratory support, SOC	216
Non-invasive respiratory support, SOC	100
Plasma based therapy, SOC	500
Positioning	300
Zavegepant (CGRP agonist), SOC	120
Plasma based therapy	2000
Plasma based therapy	357
Plasma based therapy	100
Colchicine, SOC	150
FPV, HCQ, SOC	150
Non-invasive respiratory support	440
Plasma based therapy	100
HCQ, SOC	350
RECOVERY TRIAL Conv plasma vs TCZ vs Monoclonal Abs	15000

	CHICTR2000031430	China	2021-Dec	HOSP	
	NCT04412772	United States	2021-Dec	HOSP	
	NCT04339816	Czechia	2021-Dec	HOSP	
	NCT04447469	United States	2021-Feb	HOSP	
	NCT04390594	Senegal	2021-Feb	HOSP	
	NCT04477993	Brazil	2021-Feb	HOSP	
	NCT04393246	United Kingdom	2021-Feb	HOSP	
	CHICTR2000029757	China	2021-Feb	HOSP	
	NCT04348383	Spain	2021-Jan	HOSP	
	NCT04338958	Germany	2021-Jan	HOSP	
	NCT04426695	United States	2021-Jan	HOSP	
	NCT04460183	United Kingdom	2021-Jan	HOSP	
	CHICTR2000029806	China	2021-Jan	HOSP	
	NCT04439071	United States	2021-Jan	HOSP	
		Dominican			
	NCT04363814	Republic	2021-Jul	HOSP	
	NCT04514627	United States	2021-Jul	HOSP	
	NCT04401423	United States	2021-Jun	HOSP	
	NCT04359953	France	2021-Jun	HOSP	
	NCT04414631	Switzerland	2021-Jun	HOSP	
	NCT04345289	Denmark	2021-Jun	HOSP	
	NCT04432272	United States	2021-Jun	HOSP	
	NCT04418518	United States	2021-Jun	HOSP	
	NCT04364763	United States	2021-Jun	HOSP	
	NCT04322773	Denmark	2021-Jun	HOSP	
	NCT04323514	Italy	2021-Mar	HOSP	
IR	CT20170731035423N2	Iran	2021-Mar	HOSP	
	NCT04420299	Spain	2021-Mar	HOSP	
	NCT04351763	Poland	2021-Mar	HOSP	
	NCT04476979	France	2021-Mar	HOSP	
	NCT04373733	United Kingdom	2021-Mar	HOSP	

SOC, Stem cells	200	
SOC, TCZ	300	
HCQ,	240	
Antibody to GM-CSF	573	
HCQ, HCQ + AZM	186	
JAKi, SOC	200	
Other, SGLT2 + Other, SOC	1407	
Plasma based therapy, SOC	200	
Antithrombotics, SOC	120	
JAKi	200	
mAB	2970	
Non-invasive respiratory support, SOC	300	
PD1, thymosin, SOC	120	
PTC299 (DDODH inhibitor), SOC	380	
	100	
BAKTEC-R bacterial identification, SOC	100	
Other, SOC	100	
Antihypertensive, SOC	100	
ARBs, AZM, HCQ	1600	
Conestat alfa (C1esterase inhibitor), SOC	120	
Conv Plasma	1100	
Plasma based therapy	500	
Plasma-based therapy, SOC	1200	
RBT-9 (antiviral), SOC	252	
Sarilumab, SOC, TCZ	200	
Axcorbic Acid	500	
BCC1 and Hep S, SOC	120	
Bemiparin (low molecular wt heparin), SOC	120	
CCB, Other, SOC	804	
Corticosteroids, TCZ + Corticosteroids	120	
FPV, HCQ + AZM + Zinc, SOC	450	

NCT04342221	Germany	2021-Mar	HOSP
IRCT20170922036314N4	Iran	2021-Mar	HOSP
NCT04380961	United States	2021-Mar	HOSP
NCT04306393	United States	2021-Mar	HOSP
NCT04306393	United States	2021-Mar	HOSP
NCT04306393	United States	2021-Mar	HOSP
NCT04376034	United States	2021-Mar	HOSP
NCT04366050	United States	2021-May	HOSP
NCT04379492	United States	2021-May	HOSP
NCT04333420	Netherlands	2021-May	HOSP
NCT04390464	United Kingdom	2021-May	HOSP
NCT04365985	United States	2021-May	HOSP
NCT04516915	United Kingdom	2021-May	HOSP
IRCT20200501047258N1	Iran	2021-May	HOSP
NCT04374539	Spain	2021-May	HOSP
NCT04367077	United States	2021-Sep	HOSP
NCT04415086	Brazil	2022-Apr	HOSP
NCT04478071	United States	2022-Aug	HOSP
NCT04321993	Canada	2022-Feb	HOSP
NCT04394416	United States	2022-Jun	HOSP
NCT04330690	Canada	2022-Mar	HOSP
NCT04354831	United States	2022-May	HOSP
NCT04412486	United States	2022-May	HOSP
NCT04470544	United States	2022-Sep	HOSP
NCT04364737	United States	2023-Jan	HOSP
NCT04276896	China	2023-Jul	HOSP
NCT04415060	Canada	2023-Jun	HOSP
NCT04315948	Austria	2023-Mar	HOSP
NCT04435353	Kazakhstan	NA	HOSP
CTRI/2020/05/025434	India	NA	HOSP
CTRI/2020/06/025977	India	NA	HOSP

220
112
270
200
200
200
240
560
120
390
1167
500
120
120
116
400
120
300
800
204
2900
131
100
264
300
100
752
3100
200
135
120

CTRI/2020/06/025590	India	NA	HOSP	Alternative therapy, SOC	120
CTRI/2020/04/024883	India	NA	HOSP	Alternative therapy, SOC	112
NCT04347226	United States	NA	HOSP	anti-IL8, SOC	138
NCT04401293	United States	NA	HOSP	Anticoagulants	308
2020-001972-13	Italy	NA	HOSP	Anticoagulants	300
NCT04508439	Mexico	NA	HOSP	Anticoagulants	130
NCT04372589	United States	NA	HOSP	Anticoagulants, SOC	3000
NCT04389840	United States	NA	HOSP	Anticoagulants, SOC	524
ACTRN12620000517976	Australia	NA	HOSP	Anticoagulants, SOC	206
NCT04493359	Brazil	NA	HOSP	Antihypertensive	240
NCT04328012	United States	NA	HOSP	ARBs, HCQ, LPV/r, SOC	4000
ISRCTN48734830	Sweden	NA	HOSP	ARBs, SOC	750
NCT04335786	Netherlands	NA	HOSP	ARBs, SOC	651
CTRI/2020/05/025319	India	NA	HOSP	ARBs, SOC	186
CTRI/2020/05/025271	India	NA	HOSP	BCG, SOC	480
NCT04334460	United States	NA	HOSP	BLD2660 (protese inhibitor), SOC	120
CTRI/2020/06/026192	India	NA	HOSP	C21, SOC	100
NCT04362813	United States	NA	HOSP	Canakinumab, SOC	450
NCT04328480	Argentina	NA	HOSP	Colchicine, SOC	2500
NCT04381364	Sweden	NA	HOSP	Corticosteroids, SOC	446
NCT04331054	France	NA	HOSP	Corticosteroids, SOC	436
NCT04323592	Italy	NA	HOSP	Corticosteroids, SOC	104
NCT04345614	United States	NA	HOSP	CRAC channel inhibitor, SOC	400
NCT04395105	Argentina	NA	HOSP	Dexamethasone, SOC	284
NCT04424901	United States	NA	HOSP	Dipyridamole, SOC	100
2020-001643-13	United Kingdom	NA	HOSP	DPP1 inhibitor, SOC	300
ISRCTN30564012	United Kingdom	NA	HOSP	DPP1 inhibitor, SOC	300
NCT04494984	Argentina	NA	HOSP	Equine hyperimmune serum, SOC	242
JPRN-JRCTS031190226	Japan	NA	HOSP	FPV	100
NCT04411433	Turkey	NA	HOSP	FPV, FPV + AZM, HCQ, HCQ + AZM, HCQ + FPV	1000
CTRI/2020/06/025957	India	NA	HOSP	FPV, FPV + Umifenovir	158

2020-001904-41	United Kingdom	NA	HOSP	FPV, SOC	302
CTRI/2020/06/025704	India	NA	HOSP	HCQ + AZM, HCQ + Other + AZM	120
NCT04355052	Israel	NA	HOSP	HCQ + AZM, HCQ + Other, SOC	250
NCT04392973	Saudi Arabia	NA	HOSP	HCQ + FPV, SOC	520
NCT04346147	Spain	NA	HOSP	HCQ + Imatinib, HCQ + JAKi, HCQ + LPV/r	165
2020-002035-30	Italy	NA	HOSP	HCQ, HCQ + JAKi	116
2020-000936-23	Austria	NA	HOSP	HCQ, LPV/r, Remdesivir	3100
PACTR202004801273802	Nigeria	NA	HOSP	HCQ, SOC	800
ISRCTN88057279	United Kingdom	NA	HOSP	HCQ, SOC	500
NCT04459676	Brazil	NA	HOSP	heptocyte growth factor, SOC	100
NCT04382924	United States	NA	HOSP	Ifenprodil, SOC	682
2020-001023-14	United Kingdom	NA	HOSP	IFN, SOC	400
NL8491	Netherlands	NA	HOSP	imatinib, SOC	386
CTRI/2020/04/024806	India	NA	HOSP	Imatinib, SOC	100
2020-001750-22	United Kingdom	NA	HOSP	Immunomodulators, JAKi, SOC	186
NCT04402866	United Kingdom	NA	HOSP	JAK1,SOC	159
NCT04373044	United States	NA	HOSP	JAKI, HCQ, SOC	144
ISRCTN11188345	United Kingdom	NA	HOSP	JAKi, mAb, SOC	375
NCT04404361	United States	NA	HOSP	JAKi, SOC	358
2020-001807-18	Finland	NA	HOSP	JAKi, SOC	159
2020-001759-42	Argentina	NA	HOSP	mAb, SOC	800
NCT04382651	United States	NA	HOSP	MAS825, SOC	120
	Bosnia &				
NCT04374032	Herzegovina	NA	HOSP	metenkefalin + tridecactide,SOC	120
ISRCTN40580903	United Kingdom	NA	HOSP	Mylotarg, Infliximab, Namilumab, SOC	588
2020-001236-10	Netherlands	NA	HOSP	NA	304
NCT04395807	Sweden	NA	HOSP	Non-invasive respiratory support	120
NCT04467840	Israel	NA	HOSP	opaganib (sphingosine kinase), SOC	270
2020-001805-21	United Kingdom	NA	HOSP	Oseltamivir, Oseltamivir + Other	120
2020-002229-27	United Kingdom	NA	HOSP	Other, Other + SGLT2, SOC	1407
ISRCTN60069084	Oman	NA	HOSP	Other, SOC	1180

NCT04472728	United States	NA	HOSP	
NCT04408040	United States	NA	HOSP	
NCT04393727	Italy	NA	HOSP	
NCT04344535	United States	NA	HOSP	
NCT04429854	Belgium	NA	HOSP	
NL8633	Netherlands	NA	HOSP	
NCT04479163	Argentina	NA	HOSP	
ISRCTN85216856	Ecuador	NA	HOSP	
NCT04358939	France	NA	HOSP	
NCT04366856	France	NA	HOSP	
NCT04383613	Canada	NA	HOSP	
ISRCTN54917435	Sweden	NA	HOSP	
NCT04343963	Mexico	NA	HOSP	
2020-001497-30	France	NA	HOSP	
2020-001786-36	Belgium	NA	HOSP	
2020-001573-78	United States	NA	HOSP	
2020-001453-49	France	NA	HOSP	
NCT04409262	United States	NA	HOSP	
2020-001052-18	Denmark	NA	HOSP	
ISRCTN13035264	Denmark	NA	HOSP	
NCT04359901	United States	NA	HOSP	
2020-001473-79	Italy	NA	HOSP	
NCT04389450	United States	NA	HOSP	
CHICTR2000029990	China	NA	HOSP	
NCT04366271	Spain	NA	HOSP	
NCT04393415	Egypt	NA	HOSP	
CTRI/2020/05/025369	India	NA	HOSP	
NCT04411446	Argentina	NA	HOSP	
ACTRN12620000454976	Australia	NA	HOSP	
2020-002120-37	France	NA	HOSP	
2020-002060-31	Czechia	NA	HOSP	

Other, SOC	310
Plasma based therapy	700
Plasma based therapy	126
Plasma based therapy, SOC	500
Plasma based therapy, SOC	483
Plasma based therapy, SOC	430
Plasma based therapy, SOC	210
Plasma based therapy, SOC	200
Positioning	248
Positioning, SOC	500
Positioning, SOC	350
Positioning, SOC	240
Pyridostigmine, SOC	436
ravilizumab(complement inhibitor), SOC	270
Recombinant interleukin 7, SOC	200
Recombinant interleukin 7, SOC	200
Remdesivir	2500
Remdesivir, Remdesivir + TCZ	450
Remdesivir, SOC	440
Remdesivir, SOC	400
Sarilumab, SOC	120
SGLT2, SOC	900
SOC, Stem cells	140
SOC, Stem cells	120
SOC, Stem cells	106
SOC, Stem cells	100
SOC, TCZ	180
SOC, Vitamins	1265
SOC, Zinc	160
sodium nitrite, SOC	300
SOLIDARITY TRIAL	100000

ISRCTN83971151	Argentina	NA	HOSP	SOLIDARITY TRIAL	10000
CTRI/2020/04/024773	Argentina	NA	HOSP	SOLIDARITY TRIAL	7000
NCT04417257	United States	NA	HOSP	tenretidine, SOC	240
NCT04419623	United States	NA	HOSP	TL-895 (tyrosine kinase inhibitor), SOC	146
NL8504	Netherlands	NA	HOSP	TCZ	354
NCT04378920	France	NA	HOSP	trancrocetin (NMDA inhibitor), SOC	180
2020-001264-28	Bulgaria	NA	HOSP	vidofludimus (pyrimidine synthesis inhibitor), SC	200
NCT04453384	France	NA	HOSP	XAV19(spike protein antibody), SOC	368
NCT04373707	France	NA	HOSP	Anticoagulants	602
NCT04345848	Switzerland	NA	HOSP	Anticoagulants	200
CTRI/2020/06/026193	India	NA	HOSP	HCQ +/- AZM, HCQ + Lithium +/- AZM	100
NCT04321616	Norway	NA	HOSP	HCQ, Remdesivir, SOC	700
2020-001754-21	France	NA	HOSP	JAKi + TCZ or Anakinra, SOC, TCZ or Anakinra	150
NCT04346797	France	NA	HOSP	mAb, SOC	120
NCT04347681	Saudi Arabia	NA	HOSP	Plasma based therapy	575
NCT04474340	Kuwait	NA	HOSP	Plasma based therapy, SOC	300
NCT04361253	United States	NA	HOSP	Plasma based therapy, SOC	220
NCT04401150	Canada	NA	HOSP	SOC, Vitamins	800
NCT04498936	Egypt	NA	HOSP	Sofosbuvir/Ledipasvir and Nitazoxanide, DAA, SOC	240
NCT04363853	Mexico	NA	HOSP	TCZ	200
2020-001644-25	Argentina	NA	HOSP	Acalabrutinib, SOC	177
NCT04367831	United States	NA	HOSP	Anticoagulants	100
NCT04409834	United States	NA	HOSP	Anticoagulants, Anticoagulants + Antiplatelets	750
2020-001921-30	Italy	NA	HOSP	Anticoagulants, Corticosteroids + Anticoagulants	200
NCT04371367	France	NA	HOSP	Avdirolimab (anti C5 antibody), SOC	108
NCT04355364	France	NA	HOSP	dornase alfa, SOC	100
NCT04432051	Turkey	NA	HOSP	Monitoring, SOC	100
NCT04358003	United States	NA	HOSP	Plasma based therapy	2000
NCT04350580	France	NA	HOSP	Polyvalent Immunoglbulin, SOC	138
NCT04347941	Ireland	NA	HOSP	Positioning, SOC	200
JPRN-JRCT2031200126	United States	NA	HOSP	ravilizumab (complement inhibitor), SOC	270

NCT04371393	United States	NA	HOSP
DRKS00021238	Germany	NA	HOSP
NCT04264533	China	NA	HOSP
NCT04364009	France	NA	HOSP
JPRN-JRCTS031200026	Japan	NA	HOSP
PACTR202007606032743	Egypt	NA	HOSP
NCT04263402	China	NA	HOSP
KCT0005105	South Korea	NA	HOSP
NCT04361474	France	NA	HOSP
NCT04530409	Egypt	NA	HOSP
NCT04384588	Chile	NA	HOSP
CTRI/2020/06/025803	India	NA	HOSP
NCT04425915	India	NA	HOSP
NCT04345419	Egypt	NA	HOSP
2020-001390-76	Italy	NA	HOSP
NCT04486144	United States	NA	OUTPAT
CHICTR2000029899	China	2020-Apr	OUTPAT
NCT04438850	Italy	2020-Aug	OUTPAT
NCT04337918	Canada	2020-Aug	OUTPAT
NCT04369365	Austria	2020-Aug	OUTPAT
CHICTR2000029601	China	2020-Aug	OUTPAT
NCT04466540	Brazil	2020-Aug	OUTPAT
NCT04466540	Brazil	2020-Aug	OUTPAT
NCT04438057	United States	2020-Aug	OUTPAT
NCT04406246	Mexico	2020-Dec	OUTPAT
NCT04356495	France	2020-Dec	OUTPAT
NCT04532931	South Africa	2020-Dec	OUTPAT
NCT04322682	United States	2020-Dec	OUTPAT
NCT04322565	Italy	2020-Dec	OUTPAT
NCT04334382	United States	2020-Dec	OUTPAT
CHICTR2000029741	China	2020-Dec	OUTPAT

SOC, Stem cells	300
SOC, TCZ	200
SOC, Vitamin C	140
Anakinra, SOC	240
Anticoagulants, FPV	160
Anticoagulants, SOC	100
Corticosteroids	100
Corticosteroids, HCQ + Corticosteroids, SOC	141
Corticosteroids, SOC	120
Dexamethasone	450
Plasma based therapy	100
Plasma based therapy, SOC	400
Plasma based therapy, SOC	400
remdesivir, chloroquine, SOC	120
Sarilumab, SOC	171
Alternative therapy, SOC	100
HCQ	100
Ivermectin, SOC	102
Non-invasive respiratory support	200
AZM, SOC	200
Education, Education + Herbal tea	400
HCQ, SOC	1300
HCQ, SOC	1300
Plasma based therapy, SOC	150
Niazoxanide, SOC	150
Antihypertensive, FPV, HCQ, Other, SOC	634
Antimalarial, DAA, FPV + Antivirals, SOC	250
Colchicine, SOC	6000
Colchicine, SOC	310
HCQ vs AZM	1550
HCQ, LPV/r	112

NCT04372628	United States	2020-Dec	OUTPAT	HCQ, LPV/r, SOC	600
NCT04529525	Argentina	2020-Dec	OUTPAT	Ivermectin, SOC	500
NCT04446377	United States	2020-Dec	OUTPAT	LAM002 (lysosome activator), SOC	142
NCT04425629	United States	2020-Dec	OUTPAT	mAB, SOC	2104
NCT04342728	United States	2020-Dec	OUTPAT	SOC, Ascorbic Acid, Ascorbic Acid + Zinc, Zinc	520
CHICTR2000029621	China	2020-Dec	OUTPAT	SOC, Umifenovir	380
NCT04338074	United States	2020-Dec	OUTPAT	tranexamic acid	100
NCT04464408	Saudi Arabia	2020-Dec	OUTPAT	FPV, SOC	576
CHICTR2000029780	China	2020-Jun	OUTPAT	SOC, Herbal tea	160
NCT04346667	Pakistan	2020-May	OUTPAT	HCQ, SOC	400
NCT04351191	Pakistan	2020-May	OUTPAT	HCQ, SOC	400
NCT04345991	France	2020-May	OUTPAT	Plasma based therapy, SOC	120
NCT04416399	United Kingdom	2020-Nov	OUTPAT	Corticosteroids, SOC	478
NCT04517422	Mexico	2020-Nov	OUTPAT	Nutrition, SOC	300
NCT04486313	United States	2020-Oct	OUTPAT	Antivirals + Vitamins, Vitamins	800
NCT04363827	Italy	2020-Sep	OUTPAT	HCQ, SOC	2300
NCT04332107	United States	2020-Sep	OUTPAT	AZM, SOC	2271
NCT04381962	United Kingdom	2020-Sep	OUTPAT	AZM, SOC	800
NCT04416334	Spain	2020-Sep	OUTPAT	Colchicine, SOC	1028
NCT04377711	United States	2020-Sep	OUTPAT	Corticosteroids, SOC	400
NCT04370782	United States	2020-Sep	OUTPAT	HCQ + AZM+ Zinc, HCQ + Zinc + Antibiotics	750
NCT04331600	Poland	2020-Sep	OUTPAT	HCQ, SOC	400
NCT04518410	United States	2020-Sep	OUTPAT	Other, SOC	2000
CHICTR2000033057	China	2020-Sep	OUTPAT	Rehabilitation	160
NCT04427501	United States	2020-Sep	OUTPAT	mAB, SOC	800
NCT04329923	United States	2021-Apr	OUTPAT	HCQ, SOC	400
NCT04390503	United States	2021-Apr	OUTPAT	Plasma based therapy, SOC	200
NCT04311177	United States	2021-Apr	OUTPAT	ARBs, SOC	580
NCT04523090	South Africa	2021-Apr	OUTPAT	Nitozoxanide	960
CHICTR2000029589	China	2021-Dec	OUTPAT	SOC, Herbal tea	120
CHICTR2000029539	China	2021-Feb	OUTPAT	LPV/r, SOC	328

NCT04460690	United States	2021-Jul	OUTPAT	Rapid SARS-Cov-2 detection	5000
NCT04475601	Sweden	2021-Jul	OUTPAT	Hormone therapy, SOC	500
NCT04342689	United States	2021-Jun	OUTPAT	Nutrition, SOC	1500
NCT04418505	United States	2021-Mar	OUTPAT	Alternative therapy, SOC	280
NCT04357990	Iceland	2021-Mar	OUTPAT	Alternative therapy, SOC	128
NCT04400799	Switzerland	2021-Mar	OUTPAT	Anticoagulants, SOC	1000
CHICTR2000030804	China	2021-Mar	OUTPAT	SOC, Herbal tea	128
NCT04353284	United States	2021-May	OUTPAT	Camostat, SOC	114
NCT04331899	United States	2021-May	OUTPAT	IFN, SOC	120
NCT04342169	United States	2022-Apr	OUTPAT	HCQ, SOC	400
NCT04373460	United States	2022-Dec	OUTPAT	Plasma based therapy, SOC	1344
NCT04355767	United States	2022-Dec	OUTPAT	Plasma based therapy, SOC	600
CHICTR2000030084	China	2022-Feb	OUTPAT	Psychological therapy, SOC	180
CTRI/2020/05/025490	India	NA	OUTPAT	Alternative therapy, SOC	110
NCT04404218	Canada	NA	OUTPAT	Acai Berry, SOC	480
ISRCTN13311119	India	NA	OUTPAT	Alternative therapy, SOC	116
JPRN-UMIN000040602	Brazil	NA	OUTPAT	Alternative therapy, SOC	100
ISRCTN59048638	Mexico	NA	OUTPAT	Anticoagulants, SOC	200
NCT04365582	France	NA	OUTPAT	AZM, HCQ, LPV/r, SOC	640
NCT04359329	United States	NA	OUTPAT	Estrogen steroid hormone, SOC	110
2020-002106-68	United Kingdom	NA	OUTPAT	FPV, LPV/r, LPV/r + FPV, SOC	240
NCT04346628	United States	NA	OUTPAT	FPV, SOC	120
ISRCTN86534580	United Kingdom	NA	OUTPAT	HCQ, SOC	3000
2020-001469-35	Poland	NA	OUTPAT	HCQ, SOC	400
NCT04351516	Germany	NA	OUTPAT	HCQ, SOC	350
2020-001558-23	Italy	NA	OUTPAT	HCQ, SOC	216
NCT04446429	Brazil	NA	OUTPAT	Hormone therapy + Ivermectin + AZM, Ivermectin + AZM	381
NCT04382131	United Kingdom	NA	OUTPAT	Hygiene, SOC	405
NCT04412018	Canada	NA	OUTPAT	Icosapent ethyl, SOC	100
NCT04445311	Egypt	NA	OUTPAT	lvermectin, SOC	100
NCT04414124	United States	NA	OUTPAT	KB109 (glycan), SOC	400

NCT04405570	United States	NA	OUTPAT	molnupiravir)N4-hydroxycytidine derivative), SOC
CHICTR2000029387	China	NA	OUTPAT	Ribavirin+ IFN, Ribavirin + LPV/r + IFN, LPV/r + IFN
CHICTR2000029855	China	NA	OUTPAT	SOC, Herbal tea
NCT04482673	United States	NA	OUTPAT	SOC, Vitamin D
CTRI/2020/05/025167	India	NA	OUTPAT	Thymoguinone, SOC
			OUTPAT,	
CHICTR2000030481	China	2020-Apr	HOSP	Corticosteroids, SOC
			OUTPAT,	
CHICTR2000030471	China	2020-Apr	HOSP	Nutrition, SOC
			OUTPAT,	
CHICTR2000029518	China	2020-Apr	HOSP	SOC, Herbal tea
			OUTPAT,	
CHICTR2000029974	China	2020-Aug	HOSP	SOC, Herbal tea
			OUTPAT,	
NCT04467918	Brazil	2020-Aug	HOSP	Alternative therapy, SOC
			OUTPAT,	
CHICTR2000033318	China	2020-Dec	HOSP	Exercise, SOC
		2022 5	OUTPAT,	524, 222
NCT04529499	Kuwait	2020-Dec	HOSP	FPV, SOC
NCT042244C2	Dresil	2020 Dee	OUTPAT,	
NCT04324463	Brazil	2020-Dec	HOSP	HCQ + AZM, SOC
NCT04393038	Belgium	2020-Dec	OUTPAT, HOSP	Other, SOC
110104595056	Deigiuiti	2020-Dec	OUTPAT,	otiler, soc
CHICTR2000029954	China	2020-Feb	HOSP	SOC, Herbal tea
cmcm2000023334	China	2020105	OUTPAT,	
CHICTR2000030102	China	2020-May	HOSP	Non-invasive respiratory support, SOC
	00		OUTPAT,	
NCT04338828	United States	2021-Apr	HOSP	Nitric Oxide, SOC
			OUTPAT,	,
NCT04390191	United States	2021-Apr	HOSP	Non-invasive respiratory support, SOC
			OUTPAT,	
NCT04517396	United States	2021-Aug	HOSP	BIO101 (MAS activator),SOC
			OUTPAT,	
IRCT20190810044500N5	Iran	2021-Feb	HOSP	Colchicine, HCQ + Colchicine

IEN Diberright IDV/m IEN IDV/m IEN	100
+ IFN, Ribavirin + LPV/r + IFN, LPV/r + IFN	108 180
SOC, Herbal tea	
SOC, Vitamin D	140
Thymoquinone, SOC	100
Corticosteroids, SOC	200
Nutrition, SOC	394
SOC, Herbal tea	140
SOC, Herbal tea	300
Alternative therapy, SOC	100
Exercise, SOC	104
FPV, SOC	780
HCQ + AZM, SOC	4000
Other, SOC	1034
SOC, Herbal tea	300
n-invasive respiratory support, SOC	180
Nitric Oxide, SOC	260
n-invasive respiratory support, SOC	200
BIO101 (MAS activator),SOC	300
Colchicine, HCQ + Colchicine	200

			OUTPAT,		
CHICTR2000029867	China	2021-Feb	HOSP	Carrimycin, LPV/r	520
			OUTPAT,		
NCT04394117	Australia	2021-Jan	HOSP	ARBs, SOC	605
			OUTPAT,		
NCT04419025	United States	2021-Jan	HOSP	N-acetyl ccysteine	200
			OUTPAT,		
NCT04500418	Germany	2021-Sep	HOSP	cenicriviroc (CCR2 and CCR5 receptor blocker), SOC	183
			OUTPAT,		
CTRI/2020/06/025763	India	NA	HOSP	Alternative therapy	150
			OUTPAT,		
ISRCTN14212905	United Kingdom	NA	HOSP	Anticoagulants, Other, SOC	100
			OUTPAT,		
2020-001498-63	Belgium	NA	HOSP	BIO101 (MAS activator)	465
			OUTPAT,		
CHICTR2000029573	China	NA	HOSP	cytokine derived gene protein,SOC	480
	.		OUTPAT,	571/ 60.0	400
NCT04445467	Australia	NA	HOSP	FPV, SOC	190
NCT04226222		N 1.0	OUTPAT,		100
NCT04336332	United States	NA	HOSP	HCQ, HCQ + AZM, SOC	160
	United Kingdom	NIA	OUTPAT, HOSP		020
NCT04385095	United Kingdom	NA		IFN, SOC	820
ISRCTN14241621	United Kingdom	NA	OUTPAT, HOSP	IFN, SOC	220
ISACTIN14241021		NA	OUTPAT,	IFN, SOC	220
NCT04354259	Canada	NA	HOSP	IFN, SOC	140
1010101051200	cunudu		OUTPAT,		140
2020-001860-27	United Kingdom	NA	HOSP	multiple drugs, SOC	250
			OUTPAT,		200
NCT04377308	United States	NA	HOSP	SOC, SSRIs	2000
2020-001501-24	Italy	NA	PREV	HCQ, SOC	2300
NCT04374942	Canada	2020-Aug	PREV	HCQ, SOC	988
NCT04359537	Pakistan	2020-Aug	PREV	HCQ, SOC	200
CHICTR2000029602	China	2020-Aug	PREV	Education + Monitoring + Herbal tea, Psychological therapy	600
NCT04380701	Germany	2020-Aug	PREV	BNT162 RNA Vaccine	200

NCT04334928	Spain	2020-Dec	PREV
NCT04318015	Mexico	2020-Dec	PREV
NCT04348435	United States	2020-Dec	PREV
CHICTR2000031944	China	2020-Dec	PREV
NCT04530357	Kazakhstan	2020-Dec	PREV
NCT04344379	France	2020-Jul	PREV
NCT04349228	Tunisia	2020-Jul	PREV
NCT04366180	Spain	2020-Jun	PREV
NCT04320238	China	2020-May	PREV
NCT04421391	United States	2020-Nov	PREV
NCT04466280	Iran	2020-Nov	PREV
NCT04352933	United Kingdom	2020-Oct	PREV
NCT04521322	Argentina	2020-Oct	PREV
NCT04353128	Spain	2020-Oct	PREV
NCT04313023	United States	2020-Oct	PREV
IRCT20200401046909N2	Iran	2020-Oct	PREV
NCT04405908	Australia	2020-Oct	PREV
NCT04495933	Australia	2020-Oct	PREV
NCT04384458	Brazil	2020-Sep	PREV
NCT04409327	United States	2020-Sep	PREV
NCT04303507	Thailand	2021-Apr	PREV
NCT04349371	United States	2021-Apr	PREV
NCT04312243	United States	2021-Apr	PREV
NCT04353037	United States	2021-Apr	PREV
NCT04435808	United States	2021-Apr	PREV
NCT04321928	Hungary	2021-Apr	PREV
NCT04368728	United States	2021-Apr	PREV
NCT04333732	United States	2021-Aug	PREV
NCT04449276	Belgium	2021-Aug	PREV
NCT04461379	Mexico	2021-Jan	PREV
CHICTR2000034780	China	2021-Jul	PREV

HCQ, HCQ + NRTIS, NRTIS, SOC	4000
HCQ, SOC	400
SOC, Stem cells	100
SOC, Herbal Tea	2000
QAZ-Covid Inactivated Vaccine, SOC	244
AZM, HCQ, SOC	900
HCQ, SOC	530
Nutrition, SOC	314
IFN, IFN + Other	2944
Nutrition	500
HCQ + mucodentol, mucodentol	180
HCQ, SOC	1000
lota-Carageenan	400
Melatonin, SOC	450
PUL-042 (toll-like receptor agonists, SOC	200
SOC, Vitamin D3	540
SCB019 (Clover), SOC	150
SOC, M59 sclamp Vaccine	216
HCQ, SOC	400
Other, SOC	550
HCQ, SOC	40000
HCQ, SOC	350
Non-invasive respiratory support, SOC	470
HCQ, SOC	850
HCQ, SOC	350
Education, Psychological therapy	7576
SOC, Vaccine Pfizer Biontech mRNA Vaccine	29481
HCQ, SOC	30000
SOC, CVnCov Vaccine	168
SOC, Vaccine	908
SOC, Vaccine	15000

IRCT20200411047019N1	Iran	2021-Jun	PREV
NCT04327206	Australia	2021-Jun	PREV
NCT04471519	India	2021-Jun	PREV
NCT04363450	United States	2021-Mar	PREV
NCT04448119	Canada	2021-Mar	PREV
NCT04364022	Switzerland	2021-Mar	PREV
NCT04318444	United States	2021-Mar	PREV
NCT04321174	Canada	2021-Mar	PREV
NCT04348370	United States	2021-May	PREV
NCT04364802	United States	2021-May	PREV
NCT04414267	Greece	2021-May	PREV
NCT04530396	Russia	2021-May	PREV
NCT04519437	United States	2021-Oct	PREV
NCT04456595	Brazil	2021-Sep	PREV
NCT04536051	Brazil	2021-Sep	PREV
NCT04537949	Germany	2021-Sep	PREV
NCT04466085	China	2021-Sep	PREV
NCT04372017	United States	2022-Apr	PREV
NCT04323800	United States	2022-Dec	PREV
NCT04447781	South Korea	2022-Feb	PREV
NCT04299724	China	2023-Jul	PREV
CTRI/2020/05/025275	India	NA	PREV
NCT04359680	United States	NA	PREV
ACTRN12620000417987	Australia	NA	PREV
NCT04340349	Mexico	NA	PREV
CTRI/2020/05/025067	India	NA	PREV
NCT04341441	United States	NA	PREV
ACTRN12620000501943	Australia	NA	PREV
NCT04334148	United States	NA	PREV
2020-001987-28	Italy	NA	PREV
NCT04349228	Tunisia	NA	PREV

SOC, BCG	500
Vaccine	10078
SOC, Vaccine	1125
HCQ, SOC	1700
FPV, SOC	760
HCQ, LPV/r	300
HCQ, SOC	1600
LPV/r, SOC	1220
SOC, Vaccine	1800
Hygiene, SOC	250
SOC, Vaccine	900
SOC, Vaccine Russian Gamelaya Vaccine	40000
mAb, SOC	940
SOC, Vaccine	8870
Vaccine	5000
BNT162 RNA Vaccine	120
SOC, Vaccine	900
HCQ, Vitamins	1739
Plasma based therapy, SOC	500
Device, INO4800 + Device	160
aAPC Vaccine	100
Alternative therapy, SOC	200
Antivirals, SOC	800
HCQ	680
HCQ, bromhexine, SOC	140
HCQ, SOC	6950
HCQ, SOC	3000
HCQ, SOC	2250
HCQ, SOC	2000
HCQ, SOC	1000
HCQ, SOC	530

Immun	PREV	NA	Australia	NCT04496245
Manrem	PREV	NA	Spain	NCT04452773
quinine	PREV	NA	United States	NCT04408183
	PREV	NA	South Africa	NCT04379336
	PREV	NA	United Kingdom	ISRCTN50212645
Alterna	PREV	NA	India	CTRI/2020/05/025429
A	PREV	NA	United States	NCT04343248
	PREV	NA	Sri Lanka	SLCTR/2020/011
	PREV	NA	India	CTRI/2020/06/025928
	PREV	NA	United States	NCT04344600
Ν	PREV	NA	United States	NCT04399252
	PREV	NA	India	CTRI/2020/05/025277
SOC, Inactivated S	PREV	NA	China	CHICTR2000032459
S	PREV	NA	India	NCT04475302
S	PREV	NA	United States	NCT04368988
S	PREV	NA	Brazil	NCT04369794
SOC, V	PREV	NA	United States	NCT04470427
Alterna	PREV	NA	India	CTRI/2020/06/025769
Alterna	PREV	NA	India	CTRI/2020/05/025484
Alterna	PREV	NA	India	CTRI/2020/05/025491
Alterna	PREV	NA	India	CTRI/2020/07/026560
	PREV	NA	Iran	IRCT20130306012728N8
S	PREV	NA	Germany	NCT04387409
S	PREV	NA	France	NCT04384549
HCQ + Radiation	PREV	NA	United States	NCT04381988
	PREV	NA	Spain	2020-002287-31
LNP-n0	PREV	NA	United Kingdom	ISRCTN17072692
meas	PREV	NA	Egypt	NCT04357028
SOC, G	PREV	NA	South Korea	NCT04445389
SOC, SARS-C	PREV	NA	China	NCT04470609
S	PREV	NA	Canada	NCT04439045

Immunomodulators, SOC	1000
Manremyc food supplement	315
quinine topical nasal spary	225
SOC, BCG	500
Other	2000
Alternative therapy, SOC	5000
Antivirals, SOC	800
HCQ, SOC	400
Hygiene	204
IFN, SOC	164
Nutrition, SOC	1000
Other, SOC	4000
C, Inactivated SARS-Cov-2 (Vero cell) Vaccine	288
SOC, Vaccine	2175
SOC, Vaccine	1631
SOC, Vaccine	1000
SOC, Vaccine mRNA1273	30000
Alternative therapy, SOC	40000
Alternative therapy, SOC	5000
Alternative therapy, SOC	1000
Alternative therapy, SOC	200
HCQ, SOC	500
SOC, Vaccine	1200
SOC, Vaccine	1120
HCQ + Radiation therapy, Radiation therapy	132
HCQ, SOC	1930
LNP-nCoVsaRNA Vaccine	320
measles vaccine, SOC	200
SOC, GX-19 DNA Vaccine	210
SOC, SARS-Cov-2 inactivated vaccine	471
SOC, Vaccine	3626

NCT04445428	Guinea-Bissau	NA	PREV
ISRCTN89951424	Brazil	NA	PREV
NL8547	Netherlands	NA	PREV
NCT04442048	Canada	NA	PREV
ISRCTN15281137	United Kingdom	NA	PREV
CTRI/2020/07/026352	India	NA	PREV
NCT04436276	United States	NA	PREV
NCT04412538	China	NA	PREV
RPCEC00000314	Cuba	NA	PREV
ISRCTN90906759	United Kingdom	NA	PREV
CTRI/2020/06/025861	India	NA	PREV
NCT04498442	United States	NA	PREV
CHICTR2000030937	China	2020-Aug	TAIL
CHICTR2000030720	China	2020-Aug	TAIL
NCT04368845	Greece	2020-Jul	TAIL
CHICTR2000030987	China	2020-Jun	TAIL
NCT04333589	China	2020-Jun	TAIL
NCT04394169	Spain	2020-Sep	TAIL
CHICTR2000029789	China	2021-Jun	TAIL
CHICTR2000030920	China	2021-May	TAIL
NCT04351880	United States	NA	TAIL
NCT04279197	China	NA	TAIL
CHICTR2000029578	China	2020-Apr	UNCLEAR
NCT04365309	China	2020-Apr	UNCLEAR
NCT04319900	China	2020-Apr	UNCLEAR
CHICTR2000031204	China	2020-Apr	UNCLEAR
CHICTR2000030923	China	2020-Apr	UNCLEAR
CHICTR2000029517	China	2020-Apr	UNCLEAR
NCT04326790	Gibraltar	2020-Aug	UNCLEAR
NCT04527562	Bangladesh	2020-Dec	UNCLEAR
CHICTR2000032915	China	2020-Dec	UNCLEAR

SOC, Vaccine	3400
SOC, Vaccine	2000
SOC, Vaccine	1600
SOC, Vaccine	1500
SOC, Vaccine	1112
SOC, Vaccine	1048
SOC, Vaccine	1045
SOC, Vaccine	942
SOC, Vaccine Finlay Vaccine Institute	115000
Vaccine	12330
Alternative therapy, SOC	500
Exercise, Other, Respiratory support	30000
SOC, Herbal tea	144
SOC, Herbal tea	120
Non-invasive respiratory support, SOC	100
FPV, FPV + HCQ, SOC	150
FPV, SOC	210
Rehabilitation, SOC	102
SOC, Herbal tea	100
SOC, Herbal tea	100
Meal planning	640
SOC, Herbal tea	160
Alternate therapy	1000
Antihypertensive, SOC	128
FPV, HCQ + FPV, SOC	150
HCQ, SOC	300
SOC, Herbal tea	400
SOC, Herbal tea	100
Colchicine, SOC	180
Colchicine, SOC	300
HCQ, AZM, SOC	240

CHICTR2000030219	China	2020-Dec	UNCLEAR	Herbal tea	120
NCT04447235	Brazil	2020-Dec	UNCLEAR	lvermectin + ARBs, SOC	176
NCT04323345	Egypt	2020-Dec	UNCLEAR	Nutrition, SOC	1000
CHICTR2000033320	China	2020-Dec	UNCLEAR	SOC, Herbal tea	300
CHICTR2000030288	China	2020-Dec	UNCLEAR	SOC,Herbal tea	204
CHICTR2000032098	China	2020-Jul	UNCLEAR	Herbal tea	300
CHICTR2000030480	China	2020-Jul	UNCLEAR	IFN, SOC	328
NCT04425707	Egypt	2020-Jul	UNCLEAR	lvermectin, SOC	100
CHICTR2000032399	China	2020-Jul	UNCLEAR	SOC, Herbal tea	200
NCT04334265	China	2020-Jun	UNCLEAR	Alternative therapy, SOC	750
NCT04392141	Iran	2020-Jun	UNCLEAR	Colchicine + Alternative therapy, SOC	200
CHICTR2000032237	China	2020-Jun	UNCLEAR	SOC, Herbal tea	200
CHICTR2000030034	China	2020-Jun	UNCLEAR	SOC, Herbal tea	132
CHICTR2000032400	China	2020-Jun	UNCLEAR	SOC, Herbal tea	120
CHICTR2000030490	China	2020-Mar	UNCLEAR	Herbal tea	100
CHICTR2000030535	China	2020-Mar	UNCLEAR	LPV/r + IFN, LPV/r + IFN + Other	100
CHICTR2000030188	China	2020-Mar	UNCLEAR	SOC, Herbal tea	120
CHICTR2000030810	China	2020-Mar	UNCLEAR	SOC, Herbal tea	100
CHICTR2000029550	China	2020-May	UNCLEAR	Herbal tea	300
CHICTR2000029558	China	2020-May	UNCLEAR	Herbal tea	200
CHICTR2000029549	China	2020-May	UNCLEAR	SOC, Herbal tea	400
CHICTR2000029778	China	2020-May	UNCLEAR	SOC, Herbal tea	600
NCT04405843	Colombia	2020-Nov	UNCLEAR	Ivermectin, SOC	400
NCT04355936	Argentina	2020-Oct	UNCLEAR	Antihypertensive, SOC	400
NCT04312997	United States	2020-Oct	UNCLEAR	PUL-042 (toll-like receptor agonists, SOC	100
CHICTR2000029790	China	2020-Oct	UNCLEAR	SOC, Herbal tea	120
NCT04353336	Egypt	2020-Sep	UNCLEAR	HCQ	200
NCT04325893	France	2020-Sep	UNCLEAR	HCQ, SOC	1300
NCT04429711	Israel	2020-Sep	UNCLEAR	lvermectin, SOC	100
NCT04463264	Argentina	2020-Sep	UNCLEAR	Nitazoxanide, SOC	135
NCT04338698	Pakistan	2020-Sep	UNCLEAR	Oseltamavir vs Azithromycin vs HCQ	500

NCT04449588	China	2021-Aug	UNCLEAR	BDB001 (toll like receptor agonist), SOC	368
CHICTR2000030117	China	2021-Dec	UNCLEAR	LPV/r + IFN, Herbal tea	348
CHICTR2000029935	China	2021-Feb	UNCLEAR	HCQ	100
CHICTR2000029939	China	2021-Feb	UNCLEAR	HCQ, SOC	100
NCT04421508	United States	2021-Feb	UNCLEAR	Non-invasive respiratory support, SOC	500
CHICTR2000029605	China	2021-Feb	UNCLEAR	SOC, Herbal tea	400
CHICTR2000029747	China	2021-Feb	UNCLEAR	SOC, Herbal tea	200
IRCT20110726007117N11	Iran	2021-Jan	UNCLEAR	SOC, Vitamin D	210
NCT04334512	United States	2021-Jun	UNCLEAR	HCQ, AZM, Vitamins, Zinc	600
NCT04344041	France	2021-May	UNCLEAR	,Vitamin D, SOC	260
CHICTR2000032919	China	2021-May	UNCLEAR	SOC, Herbal tea	200
NCT04395768	Australia	2021-Sep	UNCLEAR	HCQ + AZM + Zinc + Vitamins	200
CHICTR2000029756	China	2022-Feb	UNCLEAR	IFN, Herbal tea	238
CHICTR2000029976	China	2022-Feb	UNCLEAR	Psychological therapy, SOC	160
CTRI/2020/06/026221	India	NA	UNCLEAR	Alternative therapy, HCQ	100
CTRI/2020/06/025557	India	NA	UNCLEAR	Alternative therapy, SOC	420
CTRI/2020/07/026468	India	NA	UNCLEAR	Alternative therapy, SOC	140
NCT04351347	Egypt	NA	UNCLEAR	Antivirals, HCQ, Ivermectin	300
CHICTR2000032769	China	NA	UNCLEAR	Azuvidine, SOC	342
NCT04471766	Guinea-Bissau	NA	UNCLEAR	Cloth face mask, SOC	66000
CTRI/2020/05/025320	India	NA	UNCLEAR	Exercise + Nutrition + Hygiene + Alternative therapy + Other, SOC	658
CTRI/2020/06/025575	India	NA	UNCLEAR	HCQ + ribavirin, LPV/r + ribavirin	175
NCT04374019	United States	NA	UNCLEAR	HCQ, HCQ + AZM, HCQ + Ivermectin, Other	240
NCT04447534	Egypt	NA	UNCLEAR	HCQ, HCQ + Zinc	200
NCT04403555	Egypt	NA	UNCLEAR	HCQ, Ivermectin + Docycline	200
NCT04410562	Spain	NA	UNCLEAR	HCQ, SOC	714
NCT04352959	France	NA	UNCLEAR	Hygiene, SOC	178
RPCEC00000307	Cuba	NA	UNCLEAR	IFN	120
CHICTR2000029638	China	NA	UNCLEAR	IFN	100
CHICTR2000030262	China	NA	UNCLEAR	IFN, SOC	140
NCT04255017	China	NA	UNCLEAR	LPV/r, Oseltamivir, SOC, Umifenovir	400

REGISTRATION ID	Country	EXPECTED COMPLETION	SUBJECTS	AGENTS STUDIED	NO OF
					SUBJECTS
IRCT20200506047319N1	Iran	2020-Jul	HOSP	Alternative therapy, SOC	100
IRCT20200607047675N1	Iran	2020-Sep	HOSP	Alternative therapy, SOC	100
IRCT20200610047722N1	Iran	2020-Jul	HOSP	Alternative therapy, SOC	100
IRCT20080901001165N48	Iran	2020-Jul	HOSP	Alternative therapy, SOC	100
IRCT20200504047298N1	Iran	2020-Jun	HOSP	Antiretrovirals, LPV/r	100
CHICTR2000032456	China	2020-May	HOSP	Education + Non-invasive respiratory support, SOC	100
IRCT20150808023559N20	Iran	2020-Jul	HOSP	FPV + HCQ, HCQ + LPV/r	100
IRCT20200322046833N1	Iran	2020-Apr	HOSP	HCQ + Antiretrovirals, HCQ + Antiretrovirals + Umifenovir	100
NCT04343092	Iraq	2020-May	HOSP	HCQ + AZT, HCQ + AZT + Other	100
IRCT20200317046797N3	Iran	2020-Jul	HOSP	HCQ + LPV/r + Antivirals, Igs + HCQ + LPV/r + Antivirals	100
IRCT20180725040596N2	Iran	2020-Sep	HOSP	HCQ + LPV/r, HCQ + Umifenovir	100
IRCT20200418047126N1	Iran	2020-Jun	HOSP	HCQ, HCQ + Colchicine	100
IRCT20190418043307N1	Iran	2020-Jun	HOSP	HCQ, HCQ + Ivermectin	100
IRCT20200325046859N2	Iran	2020-Jun	HOSP	HCQ, HCQ + Umifenovir	100
IRCT20080901001165N53	Iran	2020-Aug	HOSP	IFN, SOC	100
IRCT20151227025726N15	Iran	2020-Jul	HOSP	LPV/r, Umifenovir	100
IRCT20200324046850N1	Iran	2020-Jul	HOSP	N-Acetyl-cysteine, SOC Vitamin D3, Vitamin D3 + N- Acetyl-cysteine	100

IRCT20200525047562N1	Iran	2020-Jul	HOSP	Plasma based therapy, SOC	100
IRCT20080901001165N58	Iran	2020-Jun	HOSP	Plasma based therapy, SOC	100
IRCT20190727044343N2	Iran	2020-Apr	HOSP	SOC, Statins	100
NCT04288102	China	2020-May	HOSP	SOC, Stem cells	100
NCT04363736	United States	2020-Aug	HOSP	TCZ	100
IRCT20120225009124N4	Iran	2020-Jun	HOSP	Corticosteroids + Igs + IFN, HCQ + Antivirals	105
IRCT20200402046923N1	Iran	2020-May	HOSP	Alternative therapy, SOC	110
IRCT20200415047092N1	Iran	2020-May	HOSP	AZT + Oseltamivir + LPV/r + Antiretroviral + HCQ, Oseltamivir + LPV/r + Antiretroviral + HCQ	110
IRCT20200411047025N1	Iran	2020-May	HOSP	HCQ + Antiretroviral, HCQ + Antiretroviral + Vitamins	110
IRCT20171122037571N2	Iran	2020-May	HOSP	Remdesivir + Chloroqines + LPV/r or Atazanavir	120
IRCT20200405046951N1	Iran	2020-Aug	HOSP	SOC, Vitamin A	120
NCT04276688	China	2020-Mar	HOSP	LPV/r, LPV/r + IFN	127
NCT04473170	United Arab Emirates	2020-May	HOSP	SOC, Stem cells	146
IRCT20200316046792N1	Iran	2020-May	HOSP	Alternative therapy, SOC	150
IRCT20200411047016N1	Iran	2020-Jun	HOSP	Alternative therapy, SOC	150
IRCT20200705048013N1	Iran	2020-Jul	HOSP	HCQ + Vitamins + Non-	150

CHICTR2000029308	China	2021-Jan	HOSP	LPV/r, SOC	160
IRCT20200325046860N1	Iran	2020-Aug	HOSP	Conv plasma, SOC	200
IRCT20160310026998N11	Iran	2020-Apr	HOSP	metformin, SOC	200
IRCT20080901001165N46	Iran	2020-Aug	HOSP	SOC, Umifenovir	200
CHICTR2000030254	China	NA	HOSP	FPV, Umifenovir	240
NCT04323527	Brazil	2020-May	HOSP	HCQ	278
IRCT20200318046812N1	Iran	2020-Jun	HOSP	HCQ + FPV, HCQ + LPV/r	324
IRCT20160316027081N1	Iran	2020-Apr	HOSP	licorice, SOC	374
NCT04327388	Argentina	2020-Jul	HOSP	Sarilumab, SOC	421
NCT04321278	Brazil	2020-Jun	HOSP	HCQ, HCQ + AZT	440
NCT04320615	United States	2020-Jun	HOSP	SOC, TCZ	450
NCT04332991	United States	2020-Jun	HOSP	HCQ, SOC	479
IRCT20200624047908N1	Iran	2020-Sep	HOSP	DAA, SOC	1000
NCT04280705	United States	2020-May	HOSP	Remdesivir, SOC	1062
NCT04292899	United States	2020-Apr	HOSP	Remdesivir	4891
IRCT20200510047383N1	Iran	2020-Aug	HOSP	SOC, TCZ	100
IRCT20200508047345N1	Iran	2020-Jun	OUTPAT	Alternative therapy	100
IRCT20200415047089N1	Iran	2020-May	OUTPAT	Alternative therapy, SOC	100
NCT04349241	Egypt	2020-Jun	OUTPAT	FPV, SOC	100
IRCT20160313027033N2	Iran	2020-May	OUTPAT	Nutrition, SOC	120
NCT04483830	Mexico	2020-Aug	OUTPAT	Anticoagulants, SOC	243
NCT04365738	Turkey	2020-Apr	OUTPAT	Education, Non-invasive	270
	-			respiratory support	
NCT04304053	Spain	2020-Jun	OUTPAT	HCQ + Antivirals, SOC	2300
IRCT20160625028622N1	Iran	2020-Apr	OUTPAT	Noscapine, SOC	125
NCT04337541	Denmark	2020-Jun	PREV	Surgical Face mask, SOC	6000
				-	

IRCT20200503047280N1	Iran	2020-Jul	PREV	Alternative therapy, SOC	300
IRCT20190122042450N4	Iran	2020-Jun	PREV	HCQ, SOC	1000
IRCT20140428017469N1	Iran	2020-Jul	PREV	oral polio vaccine	130000
NCT04308668	United States	2020-May	PREV	HCQ, SOC	1309
NCT04392219	United Kingdom	2020-Aug	PREV	EIDD-2801, SOC	130
CHICTR2000034825	China	2020-Dec	PREV	SOC,Inovio DNA plasmid vaccine	144
NCT04408456	India	2020-Jul	PREV	HCQ, SOC	325
CHICTR2000029479	China	2020-May	PREV	SOC, TCM	20000
NCT04342650	Brazil	2020-May	PREV	Chloroquine diphosphate, SOC	152
IRCT20171105037262N4	Iran	2020-Jul	UNCLEAR	HCQ, HCQ + adalimumab	100
IRCT20200410047009N1	Iran	2020-Jul	UNCLEAR	NSAIDs, SOC	101
IRCT20200408046987N1	Iran	2020-Jun	UNCLEAR	Ivermectin, SOC	125
IRCT20200404046934N1	Iran	2020-Apr	UNCLEAR	Alternative therapy, SOC	130
IRCT20180520039738N2	Iran	2020-Apr	UNCLEAR	SOC, Vitamin A	140
IRCT20131129015584N2	Iran	2020-Jun	UNCLEAR	LPV/r + AZM, LPV/r + AZM + Alternative therapy	152
CHICTR2000032165	China	2021-Mar	UNCLEAR	Education, TCM + Education	160
CHICTR2000029434	China	2020-Dec	UNCLEAR	SOC, TCM	240
CHICTR2000029433	China	2020-Dec	UNCLEAR	SOC, TCM	240
NCT04530422	Egypt	2020-Jul	UNCLEAR	DAA, Oseltamivir + HCQ + AZM	250
CHICTR2000029559 CHICTR2000029868	China China	2020-Feb 2020-Jun	UNCLEAR UNCLEAR	HCQ, SOC HCQ, SOC	300 360

NCT04523831	Bangladesh	2020-Aug	UNCLEAR	Ivermectin + Antibiotics, SOC	400
NCT04446104	Singapore	2020-Aug	UNCLEAR	HCQ, Hygiene, Ivermectin, Vitamins, Vitamins + Zinc	4257

SUPPLEMENTARY TABLE 2: TRIALS COMPLETED AS OF NOVEMBER 1, 2020. The registration ID for the respective regulatory body is given along with the country of registration and the date of completed enrolment. The setting for subjects in each trial: HOSP: Hospitalized; PREV: Healthy or exposed volunteers; OUTPAT: Infected patients, not hospitalized; UNCLEAR: Including multiple categories. SOC: Standard of Care.; FPV: Favipiravir; LPV/R: lopanovir/ritonavir; HCQ: hydroxychloroquine; AZM: azithromycin; TCM: A Chinese herbal tea; NSAID: Non-steroidal anti-inflammatory drug; Conv Plasma: Convalescent plasma